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Background and Aims In the wealth of research undertaken on myocardial infarctions 
(MIs), secondary prevention is less well studied. Incidence and death from MI have declined 
substantially in the past decades due to the identification of cardiovascular (CV) risk factors, 
methods to assess risk in the general population, development of efficient therapies that 
modify risk factor levels, and the introduction of revascularization therapies used in the acute 
phase of a MI. Meanwhile, secondary prevention in the large population of MI survivors 
performs poorly with suboptimal management and low achievement rates of the treatment 
targets recommended in major prevention guidelines. There is room for improvement. Links 
between socioeconomic status (SES) and CV risk factors, and first-ever MI have been 
reported for almost 100 years. Circumstances of contemporary secondary prevention after MI 
suggest that SES may be an important risk factor. With this thesis, aims were to improve 
knowledge on SES in secondary prevention care after MI and with regards to prognosis. 
Material and Methods This thesis was based a large nationwide cohort of men and women 
who attended routine revisits in the year after hospitalization for acute MI between 2005 and 
2013 and were registered in the Swedish National Quality Registry for cardiac care. Clinical 
data collected on study participants was linked with data from national registries manged by 
government agencies on individual-level indicators of SES (disposable income quintiles, 
educational level, and marital status), claimed drug prescriptions, and recurrent 
atherosclerotic CV disease events (ASCVD; coronary heart disease death, nonfatal MI, fatal 
or nonfatal ischemic stroke) during long-term follow-up. Multivariable Cox regression 
models were used to estimate the association between SES and recurrent ASCVD and 
between on-treatment blood lipid levels (total cholesterol, low and high density lipoprotein 
cholesterol [LDL-C and HDL-C], and triglycerides) and recurrent ASCVD. The incremental 
predictive value of each blood lipid fraction was assessed by addition to a secondary 
prevention risk score for estimates of differences in C-index and measures of reclassification. 
The associations between SES and most secondary prevention activities and risk factor 
treatment targets recommended in major guidelines on secondary prevention were assessed in 
logistic regression models. Differences in sociodemographic, clinical, and therapeutic 
characteristics of participants and non-participants in clinical trials after MI were estimated in 
Poisson regression models and the association between clinical trial participation and 
recurrent ASCVD was estimated in Cox regression models. Mediation in the association 
between SES and recurrent ASCVD was assessed using sequential Cox regression models 
and a method for mathematically consistent estimates of causal mediating effects. 
Results Risk for recurrent ASCVD was lower among study participants with higher income, 
higher educational level, and in marriage. The strongest association with recurrent ASCVD 
was observed for income and the association was independent of differences in CV risk factor 
profile. With 97% in the cohort on statin therapy at the 2-month revisit, recurrent ASCVD 
was weakly associated with achieved levels of LDL-C and strongly associated with levels of 
triglycerides. The adopted secondary prevention risk score discriminated poorly in the study 
cohort (C-index <0.6) and measures of incremental predictive power were inconsistent. Rates 
of achieved risk factor targets 1 year after MI were overall low and worse in low SES groups. 
SES was associated with achieving smoking cessation and target levels of blood pressure 
levels and glycated hemoglobin, but not LDL-C. Correspondingly, rates of participation in 
programs within comprehensive cardiac rehabilitation were also low overall, and strongly 
associated with SES. Higher SES was also associated with more lipid profile measurements 
and intensification of statin therapy during the first year post-MI. Use of risk-modifying drug 
therapy was high overall. At discharge from initial care, higher SES was associated with 
receiving dual antiplatelet therapy. One year post-MI, high SES was associated with 
persistent use of statins, high statin intensity, and renin-angiotensin-aldosterone system 
inhibitors. The 10% of this cohort who participated in a clinical trial during the first year after 
MI (compared to those who did not) were more likely to be men, married, have an income in 
the highest quintile, a post-secondary education, a better risk profile, and their risk for 
recurrent ASCVD was lower. In the association between SES and recurrent ASCVD, risk 
attenuated in sequential analysis models, primarily from adjustment for risk factor profile and 
secondary prevention activities but a 37% higher risk remained in the lowest vs. highest 
income quintile after full extensive adjustments for plausible risk mediators. Estimated 
proportions of the excess risk for recurrent ASCVD in the lowest income quintile mediated 
through risk profile, physical training and patient education within cardiac rehabilitation were 
significant but small whereas optimal statin therapy was not a mediator of this risk. 
Conclusions SES, by proxy disposable income level, may be a better measure than on-
treatment lipid levels in the assessment of risk for recurrent ASCVD within the post-MI 
population. More study is needed to improve secondary prevention risk prediction, for risk-
based intensified treatment to those who would likely benefit most. Secondary prevention 
after MI performs poorly, especially among low-income groups. Observed SES disparities 
regarding participation in programs within cardiac rehabilitation were mediators for higher 
long-term risk of recurrent ASCVD events. Hence, interventions for improved cardiac 
rehabilitation participation in low-income groups may improve health equity. However, the 
mediating proportions were small and plausible effectiveness of interventions warrant 
evaluation of efficacy in clinical trials. Awareness of under-representation of low SES 
individuals among trial participants within the post-MI population must be taken into account 
in designing such confirmatory trials. Further study on pathways through which low SES is 
associated with secondary prevention achievements and higher risk for recurrent ASCVD is 
needed. Adherence to therapies and dietary habits may be important areas to study.   
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Within a patient population, the individual with the highest risk of an adverse outcome have 
the greatest need for more intense treatment and will also benefit the most from it.1 This 
principle has been the focus of management in primary prevention of incident atherosclerotic 
cardiovascular disease (ASCVD) events, fatal or nonfatal myocardial infaction (MI) or stroke 
for decades.2,3 
Despite concerns regarding the accuracy of risk prediction algorithms and the evidence for 
use4,5, application in primary prevention has been successful.6 Combined with an ageing 
population and dramatically improved survival of incident ASCVD events, the population 
with manifest disease in need for secondary prevention has grown large. Risk-based 
individualized treatment intensity should be provided also after MI.7 However, assessment 
and stratification of risk is by comparison absent in the large population in the stable phase 
after MI8,9 and overall, secondary prevention management performance is poor.10,11 
It is well known that low socioeconomic status (SES) is linked to cardiovascular (CV) risk 
factors and events in primary prevention12-14, and SES may be considered a “cause of the 
causes” for ASCVD.15,16 There is reason to believe that contemporary secondary prevention 
after MI may amplify the importance of SES as a risk factor for subsequent CV events. 
Especially in relation to more established CV risk factors that are specifically targeted with 
efficient risk factor modifying therapies. 
The risk for death and worsened burden of disease is most hazardous in the acute phase of a 
MI. With time, risk levels decline.9,17 One year after a MI, residual risk for recurrent ASCVD 
is still elevated compared to the general population but at a stable level. A more stable 
residual risk is more predictable. Routine revisits after MI are therefore ideal for long-term 
secondary prevention risk assessment. Furthermore, these are patient – cardiac care provider 
interactions where decisions on continued, corrected, or intensified treatment are made. 
The prerequisites for high-quality registry-based research is good in Sweden. In this thesis, 
the role of SES in secondary prevention after MI is evaluated, in relation to other CV risk 
factors and prognosis. Through these studies, this thesis seeks to improve risk assessment for 





2 LITERATURE REVIEW 
2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 
2.1.1 Atherosclerosis 
Atherosclerosis is a slowly progressing chronic pathological process of the arterial wall.18 
The process is intricate and involves focal intramural depositions of blood lipid particles, low 
density lipoprotein cholesterol (LDL-C), and immune system activation. LDL-C particles are 
oxidized and aggregated in the intramural environment which triggers an innate immune 
respone and attracts several types of immune cells. Macrophage uptake of aggregated 
oxidized LDL-C forms foam cells in the artery wall. Further activity from enzymatic, 
inflammatory, and cell necrosis pathways maintain previous steps and causes vascular 
smooth muscle cells to transform and proliferate.19 Smooth muscle cells also migrate from 
the mid-wall to the subendothelial space. The inner layer of the artery becomes incresingly 
thickened and in later stages, a collagen-rich fibrous coat is formed that encapsule a core of 
aggregated foam cells and extracellular necrotic fatty content – an atherosclerotic plaque has 
formed. By now, the inner lining of the artery is irregular. Large plaques that narrow the 
lumen considerably may cause symptoms at times when the demand of blood flow and 
oxygen in downstream tissues increase. In cases of a MI however, the fibrous cap of a plaque 
has nearly always become thin and ruptured for reasons that are not fully understood.20 
Exposed non-endovascular tissue at the site of rupture triggers adherence, activation, and 
aggregation of blood platelets as part of normal primary haemostasis and a cascade of 
circulating coagulation factors of secondary heamostasis. Consequently, a thrombus forms 
and blood flow is obstructed, causing ischemia and eventually necrosis of downstream 
dependent tissue.18 
2.1.2 Myocardial Infarction 
A universal definition is used for the diagnosis of an acute MI. The definition was first 
released in year 2000 and in 2018, the fourth edition was published.21 Typically, diagnosis 
requires typical dynamics of serially measured biomarker-levels associated with myocardial 
necrosis and either symptoms characteristic of myocardial ischemia, ischemic 
electrocardiogram (ECG) changes, or cardiac imaging evidence such as echocardiographic 
wall motion abnormalities or evidence from coronary angiography, or autopsy. The vast 
majority of MIs are the sudden acute pinnacles of decade-long development of 
atherosclerosis.20 However, an acute MI, correctly diagnosed according to the criteria, may 
also be due to non-atherosclerotic mechanisms. These subtypes include MIs caused by 
coronary interventions, or temporary supply and demand mismatch of oxygen delivery to the 
myocardium. Additionally, a fairly large proportion of MIs have emerged in recent years 
parallel to the increasing availability of imaging techniques. Within this heterogeneous group 
with MI, no obstructed coronary arteries are found by angiographic examination.21 
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2.1.3 Atherosclerotic Cardiovascular Disease 
In this thesis, MI and ischemic stroke are referred to as ASCVD events. CV diseases that are 
manifestations of atherosclerosis also include less prevalent peripheral arterial disease and 
diseases of the aorta. According to the 2020 WHO Global Health Estimates, ischemic heart 
disease is by far the overall leading cause of death worldwide accounting for approximately 
8.9 million deaths, or 16% of all deaths annualy. The runner up, stroke, was accountable for 
11% of world deaths.22 In 2004, the WHO projected that the incidence of CV diseases would 
increase in low- and middle-income countries. Furthermore, they projected that economic 
development in these countries would result in unhealthier lifestyle including physical 
inactivity, high-fat diets, obesity and diabetes, combined with increased life expectancies. 
Unfortunately, this prognosis seem to have come true.22,23 
Myocardial infarction and stroke are also major contributors to global morbidity as measured 
by an international standardized measure; number of years lived with disability (YLDs), that 
is weighted for health condition severity. Increasing global trends for YLDs were observed 
between 1990 and 2019.24 Countries across the world are urged to reverse these trends 
through multisectoral interventions of fundamental drivers of ASCVD including 
socioceonomic status and unequal access to quality health care and prevention.24 
The economic consequences of ASCVD for society are not easily determined on a global 
scale because of absent or low quality data. However, direct health care expeditures due to 
CV disease in Sweden has been estimated to account for more than 10% of total costs and 
accounted for the largest share of spendings on inpatient care and drugs.25 Indirect costs for 
society attributable to CV disease may also be measured. Disease-related loss of productivity 
may be assessed by adding a measure of premature death (years of life lost) to YLD for 
disability-adjusted life years (DALYs). Thus, DALYs combine mortality and morbidity and 
represent years of living with “ideal health” that are lost because of a disease. In 2019, 
ischemic heart disease remained the leading cause of DALYs in Sweden with roughly 2,000 
DALYs per 100,000 Swedish citizens, and was the second leading cause of DALYs 
worldwide after neonatal conditions.26 Productivity-loss because of unpaid care by family 
members remain unaccounted for. 
2.1.4 Cardiovascular Risk Factors 
In 1913, it was experimentally established that cholesterol-fed rabbits developed coronary 
atherosclerosis.27,28 The epidemiological field of CV research and conceptualization of CV 
risk factors was initiated around 1950. Two cardiologists, sceptics of “the dietary theory” for 
atherosclerosis29, launched a case-control study in 1946 that is often referred to as the first 
CV epidemiological study.30 In this study, the clinical characteristics in common among 100 
young individuals with premature MI were described: male sex, cigarette smoking, family 
history, elevated levels of cholesterol and blood pressure, and body type.31,32 The concept of 
CV risk factors was further established through several longitudinal and observational 
studies. Among these, the multinational Seven Countries Study and the Framingham Heart 
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Studies have been particularily recognized.33 In the Seven Countries Study, one of the 
important insights was that dietary fat intake and lifestyle was linked to cholesterol levels and 
ASCVD.34,35 The Framingham Heart Studies have contributed greatly to the understanding of 
combinations of risk factors for total risk of CV outcomes and much more.36 New candidates 
as risk factors for ASCVD have been evalutated throughout the years, including alternative 
ways of measuring risk factors, novel biomarkers, and advanced measurements of subclinical 
atherosclerosis. Although strongly associated with CV outcomes, few have been proven 
meaningful additions to risk assessment in relation to the risk factors identified decades prior. 
Traditional risk factors are those most widely recognized overall. Among the more recent 
global epidemiological studies that have made a large footprint on what may be considered 
traditional CV risk factors was INTERHEART.37 In this large international case-control study 
published in 2004, nine risk factors (dyslipidemia, smoking, hypertension, diabetes, 
abdominal obesity, psychosocial factors, inadequate consumption of fruits and vegetables, 
high alcohol consumption, and physical inactivity) were highlighted as being responsible for 
90% of all MIs worldwide in both sexes regardless age group. INTERHEARTs results 
aligned well with risk factors consistently identified in earlier epidemiological studies. 
Expert workgroups of the major international CV societies regularly evaluate, summarize, 
and report the existing evidence in clinical guidelines. The most recent editions on CV 
prevention, the 2013 American College of Cardiology / American Heart Association 
(ACC/AHA) Guideline on the assessment of CV risk3 and the 2016 European Society of 
Cardiology (ESC) Guidelines on CV disease prevention in clinical practice38, highlight 
essentially the same risk factors: age, gender, smoking, dyslipidemia, hypertension, and 
diabetes. Differences are minor, such as the specification of lipid fractions 
(hypercholosterolemia and low HDL-C vs. LDL-C and triglycerides) and only the U.S. 
guideline considers the absence of an intervention, antihypertensive treatment, a risk factor. 
The European guideline is less selective and additionally emphasizes the importance of 
physical inactivity and body composition as risk factors as well as previously documentated 
ASCVD and chronic kidney disease. 
WHO and the International Society of Hypertension has published a guideline on the 
prevention of CV disease as well in which the traditional CV risk factors and their 
management are addressed one by one in detail.39 A main application of clinical guidelines is 
for health care professionals to find recommendations on clinical management according to 
the best available evidence in real-time. CV risk factors may be classified and viewed upon 
from a wider perspective than what is sought after in the busy clinical setting.40 The WHO 
Commission for Social Determinants of Health presented a conceptual framework for health 
and health equity improvements in which risk factors are categorized differently: true CV risk 
factors are all behavioural: unhealthy diet (excessive dietary salt, insufficient fruits and 
vegetables), physical inactivity, use of tobacco, and alcohol excess. Risk factor that are 
immediate causes of disease and most regarded in clinical practice: hypertension, 
hyperlipidemia, diabetes, overweight and obesity are “intermediate risk factors” attributable 
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to the former. Furthermore, the conceptual framework considers SES a “cause of the causes” 
for ASCVD that follow globalization, urbanization, and ageing populations. That is, a risk 
factor shaped by the daily life circumstances and social structures that determine behavioral 
risk factors, that underly the intermediate risk factors that in turn are measured and acted 
upon in clinical assessment for ASCVD risk.15,41,42 
2.2 SOCIOECONOMIC STATUS 
In lack of a clear definition, SES may be described as a measure of an individual’s position in 
the hierarchy of a society, according to the opinion of the average member of that society.13 
Many aspects may influence said position. An aspect of SES may be considered more 
important for a specific setting than another, and two societies may not value the same aspect 
equal. SES should ideally take into account both resources and prestige-related aspects.43 The 
most frequently used and acknowledged indicators of SES are level of income, educational 
attainment, and occupational status. Other indicators used are wealth, level of social support 
including marital status, and various neighbourhood characteristics such as rural 
residency.44,45  
In research, availability of reliable data influence which SES indicators are used. Sometimes 
indicators are used alone, in different combinations and sometimes without definition of the 
indicator(s) used. It is recommended that multiple indicators of SES should be used in 
research to capture this complex and multifaceted construct.44,45 In a studied population and 
setting, the educational level may differ between individuals within a category of 
occupational status, and differences in occupational status may exist among individuals with 
the same educational level. It is further recommended that plausible explanatory pathways 
and mechanisms are considered and that unmeasured indicators of SES may affect findings.45 
The multiple indicators of SES available, and relevant, should be included in analyses 
simultaneously.44 Sometimes, multiple SES indicators are joined into a single SES-index that 
is convenient for undertaking analyses and for comparisons within the study but this practice 
is not recommended. First, since the selection of SES indicators used should be determined 
by the study question and society studied, no SES-index among indices with various 
compositions is universally applicable to all settings and outcomes. Second, while the 
inclusion of multiple indicators into a single SES-index make analyses less complex and less 
sensitive to missing data on single SES indicators, an observed difference in SES-index level 
may actually compare two different indicators. Third, in interpretation of study findings, 
reference to a SES-index gives no lead with regards to explanatory pathways.45 
Plausible pathways in which SES affect outcomes are patient compliance to therapy46, 
cognition and health literacy47, travel distance to health facilities, cost of work-absence for 




2.3 SOCIOECONOMIC STATUS IN CARDIOVASCULAR DISEASE 
Abundant support for an inverse relationship between SES and most traditional CV risk 
factors and first incident CV events is available in the literature since the 1950s.14,49 It has 
been suggested that all observations of associations between SES and adverse health 
outcomes amount to evidence of causality.16 Even prior to the conceptualization of CV risk 
factors, an association between SES and atherosclerotic lesions was described at the 
International Society of Geographical Patology conference in 1934.33,50 
It is acknowledged in recent major CV prevention guidelines that SES should be considered 
with regards to risk for morbidity and mortality in primary prevention. However, SES is not 
only a complex construct. SES is generally considered a non-modifiable risk factor. As such, 
there is no treatment to prescribe against low SES in the clinical setting. Just as there is no 
treatment that modifies biological age or gender. Considering the well known association 
between SES and prevalence of traditional modifiable CV risk factors, management in low 
SES groups has predominantly been focused on these risk factors.12  
2.3.1 Wider Perspective 
In this thesis, individual-level SES is studied. SES may also be considered at higher levels. 
Gross Domestic Product (GDP) is a measure of the economic growth and can be used to 
describe the financial state of a country. The resources available for a health care system in 
turn determine the quality of care provided to the citizens of a country. For this, and other 
reasons, initiatives to assess the global burden of CV diseases compare global subregions or 
low-, middle-, and high-income countries separately.24 Also within a relatively wealthy 
continent, Europe, higher-GDP countries have much greater relative and absolute healthcare 
expeditures than middle-income countries. This is reflected in the utilization of best available 
therapies for MI as well as incidence of MI, stroke, mortality, and morbidity due to CV 
disease.25 Domestic average income-level has also been used as an indicator of SES to 
compare quality-of-care and long-term outcomes in secondary prevention after MI between 
European countries.51 In addition to national economic growth and average income levels, 
countries differ with regards to the Health Care System used.  
2.4 SWEDISH PERSPECTIVES 
Sweden is a wealthy country with universal health coverage and strong social security. 
Hence, the conditions for health equity in Sweden are good.52 Additionally, Swedish health 
care providers are obliged by law to follow three ethical principles in prioritization for care. 
The Swedish Healthcare Law (Hälso- och sjukvårdslagen, HSL) states:53 
The principle of human equality 
(SFS 2017:30 3 kap. 1 §) 
 Health care shall be provided with respect for the 
dignity and equal value of all human beings. 
The principle of demand and solidarity 
(SFS 2017:30 3 kap. 1 §) 
 Those in greatest need for health care should be 
given priority to access.  
The principle of cost-efficiency 
(SFS 2017:30 4 kap. 1 §)   
 Publicly financed health care shall be organized in 
order to promote cost-efficiency. 
Free translation by the author of this thesis 
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The first principle resembles the first article of the United Nations declaration of human 
rights.54 An interpretation is that care should be provided without regard for SES as well as 
chronological age, gender, lifestyle, societal function, and ability to pay. Further, that high-
risk groups should be better identified and that health care providers and decision makers 
should allocate resources to high-risk individuals. Cost-efficiency is a subordinate healthcare 
law but importantly points out the necessity of maximizing benefit from common resources at 
the individual as well as societal level with regard for disease prevalence and severity. 
However, previous studies on SES in CV disease conducted in regions of Sweden indicated 
that socioeconomic disparities exist in primary prevention between neighborhood-SES and 
incident MI55, in early-phase secondary prevention regarding use of evidence-based drug 
therapy56, and for long-term mortality.57 
2.4.1 Myocardial Infarction Trends in Sweden 
MI remains the most common cause of death and disability in Sweden. Almost 30,000 MIs 
occured in 2013 (383 per 100,000 citizens) according to official statistics. One fifth (18%) 
died within a day of MI and one out of four (26%) died within a month.58,59 Among cases 
hospitalized, the population most relevant for this thesis, the 28-day case fatality was 11%. 
Among the 5300 individuals who died within a day of the MI, 93% were not admitted to 
hospital. Although the incidence and fatality-rates are high, remarkable improvements have 
been achieved in the past years. The incidence of MI decreased by 38% between 2001 and 
2014. The 28-day case fatality rate among hospitalized individuals with MI decreased by 
50% between 1994 and 2014.58 The decreasing case-fatality rates after MI started more than 
20 years ago. However, further survival gains beyond 1 year seem to be reaching a plateau in 
the most recent years.60 
2.5 EVIDENCE-BASED CARDIOVASCULAR MEDICINE 
The Swedish Society of Cardiology is part of the ESC, a major international non-profit 
organization for CV professionals. The existing litterature on CV diseases is extensive and 
the influx of new findings high. It is a necessity for clinical usefulness, comprehension, and 
concistency of care that the available research is regularily and systematically reviewed, 
evaluated for evidence, and condensed into clincial practice guidelines. This work is 
preferably conducted by experts in the specific field of research and disseminated through an 
authoritarian and trustworthy professional organization.61 Swedish cardiac care providers 
generally follow the clinical practice guidelines issued by the ESC. Numerous guidelines 
exist that cover areas of different comprehension within CV medicine. Strong 
recommendations warrant high level of evidence. Just as clinical practice guidelines, meta-
analyses and systematic reviews are based on previous original work that is synthesized and 
provide the highest level of evidence. Among original studies, randomized controlled trials 
provide the highest level of evidence. This is because the study design allows for elimination 
of confounding (systematic errors) and determination of causality. Trials are expensive to 
conduct and require strict inclusion and exclusion criteria during enrollment of study 
participants. It was recently reported that among recommendations in ESC and counterpart 
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U.S. guidelines, a very small proportion are supported by large or multiple randomized 
trials.62 Better evidence is needed. However, not all hypotheses can be answered by a clinical 
trial and may not be ethically or financially justifiable. For example, it is not feasible to 
randomize an individual to a level of SES and it would not be ethical to randomize an 
individual to take up cigarette smoking. In some instances, a wealth of consistent data from 
observational data may amount to causal inference.16 Furthermore, there is an Achilles heel to 
randomized clinical trials – external validity. Because of the strict selection criteria of the 
study population (in which an intervention was evaluated), findings may not be generalizable 
to the population in which an intervention is intended to be used. The selection process of 
participants to clinical trials may be yet another area of CV disease where SES play a role. 
2.6 CARDIOVASCULAR PREVENTION ACHIEVEMENTS 
ASCVD prevention may be divided into three phases: primary prevention, acute phase, and 
long-term secondary prevention. Each phase is characterized by differences in risk 
mechanism for recurrent ASCVD, level of risk within the population, and available methods 
for risk assessment that determine management for risk reduction. (Figure 1) 
 
Figure 1. Prevention phases.  
Abbreviations: HTN, hypertension. LLT, lipid lowering therapy. 
Intense research and development of efficient therapies over the past decades has been a 
major contributor to the declining MI incidence and mortality in Sweden and other high-
income countries. Primary prevention treatment of CV risk factor has been attributed to 




2.6.1 Improved Primary Prevention 
With the advancement of identifying CV risk factors associated with ASCVD, equally 
important development followed in efficient interventions to modify risk factor levels. 
Another extension of knowledge was the understanding that the overall risk of ASCVD for an 
individual was the product of the prevalence, severity, and number of traditional risk factors 
in that individual. International guidelines advocate that primary prevention treatment takes 
into account that a person's total CV risk varies widely in the population.3,38,39,65 Risk 
assessment tools such as the ESC SCORE, Framingham Risk Scores and New Pooled Cohort 
Risk Equations generate estimates of the risk for future CV manifestations in an individual 
based on the prevalence and levels of established CV risk factors with predictive 
properties.2,3,66,67 Thereby, decisions on treatment intensity can be individualized and risk-
based. Successful broad implementation and a general awareness of CV risk factors in society 
are also part of the improved primary prevention. Treatment of CV risk factor levels lowers 
the progression rate of atherosclerosis causing delay or inhibition of acute manifestations.  
2.6.2 Introduction of Acute Phase Interventions 
Early revascularization of obstruced coronary arteries have been proven time-critial for MI-
survival. Systemic treatment with fibrinolytic agents may dissolve an obstructing coronary 
thrombus but also poses the risk of lethal side effect from bleedning elsewhere. Coronary 
artery bypass grafting (CABG) has been an option for over 50 years and is the most frequent 
type of heart surgery procedure worldwide.68 During CABG, a graft vein is transplanted to 
the coronary arteries in order to bypass segments of widespread advanced atherosclerosis for 
blood supply to downstream cardiac tissue. Percutaneous coronary intervention (PCI), was 
first performed in 1977 and is a minimally invasive endovascular catheter based therapy. 
Developments of the technique until the new millenia made PCI safe, reliable, and more 
efficient for improved outcomes. Typically, a catheter is introduced via the radial artery and 
angiography is performed including identification of the coronary culprit lesion(s). In the 
same session, a guide wire is passed through the lesion. This allows for a balloon and drug-
eluding metal stent to be passed over the wire to the site of the lesion. The stent is then 
deployed by expanding the balloon whereafter blood flow can be restored. The introduction 
and further development of PCI has revolutionized acute cardiac care. With growing 
evidence of efficiency and increasing availability, PCI has become the treatment of choice in 
STEMI.69,70 PCI is also recommended for NSTEMI, but may be performed with delay unless 
the clinical presentation calls for urgency.71,72 Fairly recent trials have demonstrated superior 
long-term survival after CABG than after PCI in patients with complex multivessel coronary 
disease.73 In Sweden, CABG remains an option in patients with complex coronary disease 
who are fit for thoracic surgery and recovery in a subacute or elective setting. Systemic 
thrombolytic therapy remains a rescue treatment in rare cases where transportation to a 
catheterization lab for PCI would substantially delay revascularization.  
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2.6.2.1 Acute Phase Risk Scores  
The risks of CV events and death peak in the immediate period following a MI, declines 
sharply within the first few days and more gradually in the following months. In a Swedish 
cohort of almost 100,000 patients hospitalized for MI between 2006 and 2011, the one-year 
risk of recurrent MI, stroke or CV mortality was about 18% as compared to approximately 
7% in the years following.17 The risk mechanisms of new MI and death in the populations in 
acute phase after MI is not primarily progression of atherosclerosis. (Figure 1) 
Decompensated heart failure may be induced by the loss of viable myocardium, initial 
stunning of surrounding myocytes or cardiomechanical complications. Infarcted regions of 
the myocardium are also prone to trigger fatal arrhythmias. Early reinfarctions more likely 
relate to thrombosis of unstable ruptured plaques or implanted coronary stents.69 
Every MI is an urgent medical matter but not all MIs are life threatening. Potent therapies 
available for acute coronary care also carry risk of serious complications. Therefore, the 
appropriate intensity and urgency of therapies are chosen based on available health care 
resources and individual risk assessments. The most hazardous MIs are preferably identified 
by prehospital crews for time-saving transport directly to coronary intervention facilities.69 
Among remaining MI patients, risk level is determined by acute symptoms, measures of MI 
severity, and other risk factors and comorbidities. Acute-phase risk score algorithms74,75 are 
superior to clinical risk assessment and therefore recommended at admission for MI to guide 
priority to definitive procedures and therapies.70,71  
2.6.3 Introduction of Efficient Drug Therapies 
Drug therapies have constantly been developed and evaluated alongside increasing 
knowledge about atherosclerosis, underlying causal mechanisms, and CV risk factors. 
Briefly, the importance of antithrombotic therapy in the acute phase of MI is intuitive 
considering that the tipping point for manifestation of a ruptured atherosclerotic plaque is 
thrombus formation. Both platelet inhibition and anticoagulants are used aggressively.69,71 In 
addition, antithrombotic therapy is required to prevent clot formation from catheterization 
during PCI and stent trombosis.72 Furthermore, antithrombotic therapy prevents new MIs 
from occurring in the acute phase of MI. Four groups of drugs that are typically initiated in 
the acute phase of MI are evidence-based therapies also in secondary prevention after MI: 
Antiplatelet therapy with acetylsalicylic acid is a cornerstone treatment in acute MI as 
discussed above and also in the long-term secondary prevention of recurrent MI.76 A second 
antiplatelet drug is recommended in addition to acetylsalicylic acid for 12 months after MI. 
This protects from thrombus formation due to platelet adhesion to coronary stent material 
until the stent is covered by endothelium. Moreover, the MI induces a highly prothrombotic 
inflammatory state in itself. Although MIs managed with drugs alone are less likely to receive 
prolonged dual antiplatelet therapy77, there is Level A evidence and a Class I 




Lipid lowering therapy with statins is supported by strong evidence of secondary prevention 
risk reduction for recurrent ASCVD events.80 Statin therapy also lowers levels of LDL-C, a 
key component in the causal pathway of atherosclerosis81, and may additionally carry 
pleiotropic effects including anti-inflammatory effects. Statins, lipid lowering, and LDL-C 
will be discussed in more detail further on in this thesis frame. 
Renin-angiotensin-aldosterone system (RAAS) inhibitors are a group of drugs that inhibit 
an endocrinological system important in regulation of blood pressure and electrolytes. RAAS 
also affects the reparatory phase during which myocardial scar tissue is formed. The heart is 
continuously regulated by neurohormonal factors for adequate cardiac output and the 
ventricular wall is under continuous mechanical strain. These complicating circumstances for 
repair may initially expand the infarct zone, distort the ventricular shape, cause arrhytmia-
prone myocardial hypertrophy surronding the scar, and worsen chronic heart failure. The 
degree of remodelling is proportional to the size of the infaction and local inflammatory 
response. RAAS play an important role in post-infarction remodelling. With early initiation 
of RAAS-inhibition, the reparative response is modulated and outcome improves.82 
Additionally, RAAS-inhibition is beneficial in chronic heart failure, and for CV risk factors 
hypertension, diabetes, renal disease, or combinations thereof. 
Beta blockers target the sympathetic nervous system by inhibiting the effect of 
catecholamines. Beta blockers have anti-arrhytmic properties, reduce myocardial oxygen 
demand and improve coronary blood flow. Many trials supporting use in acute MI and 
secondary prevention were conducted in the 1980s.83,84 More efficient therapies have evolved 
since then, in particular revascularization therapies. Alongside decreasing mortality rates, the 
role of beta blocker therapy in MI has been increasingly questioned. Studies in contemporary 
populations show lower rates of short-term recurrent MI but no short-term mortality benefit.85 
Treatment among post-MI patients with reduced left ventricular ejection fraction (LVEF) 
remains a guideline recommendation but epidemiological and longitudinal data on beta 
blockers in long-term secondary prevention are inconsistent.86 An ongoing registry-based 
randomized clinical trial will investigate the efficiency of long-term beta blockers in patient 
with MI and preserved left ventricular ejection function.87 
2.7 SECONDARY PREVENTION IN STABLE PHASE AFTER MYOCARDIAL 
INFARCTION 
2.7.1 Population Characteristics 
Development of primary prevention and acute cardiac care have strongly contributed to 
reducing mortality after MI by half over the past decades.6 As a consequence, the post-MI 
population living in Sweden has grown large. The ESC and counterpart organizations 
continuously produce new and updated guidelines on different aspects of cardiac care. 
However, the most recent guidelines specifically dedicated to secondary prevention was 
released in 2011.8 A common denominator among MI survivors is that the first-ever ASCVD 
event attests to several years worth of systemic atherogenesis prior. Hence, new critical 
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obstructions and occlusions may occur elsewhere in the arterial system. Indeed, the risk of 
new ASCVD is elevated in the long-term secondary prevention population compared to in the 
general population. But lower and settled at a stable level after the first most hazardous 
months when many of the most frail patients die.17  
2.7.2 Secondary Prevention Therapies 
Months after a MI, the mechanism of CV risk reverts to progressive atherosclerosis again.9,17 
(Figure 1) Hence, post-MI treatment in the stable secondary prevention phase is long-term 
and a matter of risk factor reduction. The well-established traditional CV risk factors are 
targeted. Evidence-based drug treatments initiated during the acute phase have been 
described above. In addition, participation in cardiac rehabilitation is a cornerstone 
intervention of secondary prevention.38,88 Cardiac rehabilitation is a multidisciplinary lifestyle 
intervention. Based on a set of structured programs, comprehensive cardiac rehabilitation is 
designed to address underlying causes of the traditional risk factors including physical 
inactivity, health illiteracy, unhealthy diet, mental health89,90, and smoking91. Exercise-based 
cardiac rehabilitation is particularily important as rates of reinfarction and deaths are reduced 
from participation.92 A 2016 Cochrane review found evidence of reduced rates of 
rehospitalizations and improved quality-of-life, and CV mortality.93 Exercise-based cardiac 
rehabilitation is also cost-efficient.94 Still, referral and participation rates are low.95 Married 
post-MI patients are reportedly 2 times more likely to attend cardiac rehabilitation than 
unmarried96 Danish researchers have demonstrated that low SES groups are more likely to be 
non-attendees to cardiac rehabilitation97, and that attendance rates and secondary prevention 
target achievements improve if low SES-groups are selectively offered extended cardiac 
rehabilitation.98 
2.7.3 Unstratified Risk and Intensity of Therapies 
Unlike in primary prevention and short-term follow-up in the acute phase2,75, no method for 
risk stratification has been established specifically for the long-term secondary prevention 
population.3,8,38 Patients with a previous MI are considered in the ESC prevention guideline.38 
The ESC SCORE algorithm, recommended for assessment and stratification of individual 
total risk, instructs that patients in stable phase secondary prevention bypass the actual risk 
algorithm and are stratified to the “very high risk” category by default which is equivalent to 
an estimated 10-year risk of CV mortality higher than 10%. Recommended management and 
intensity of therapy is undifferientiated within this risk category (Figure 1). Moreover, 
patients with other types of manifest ASCVD, type 2 diabetes or type 1 diabetes with organ 
damage, or chronic kidney disease are also categorized to the “very high risk” group by 
default.2 The most recent ESC guideline on chronic coronary disease recommend that 
caregivers consider regular revisits for patients in stable phase after MI. Risk assessment 
using unspecified “risk score(s)” for risk stratification are mentioned but without evaluation 
of evidence or recommendations.9 Further discussion on secondary prevention risk scores 
will come later in this thesis frame. 
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The lack of differentiation by presence, number, and severity of risk factors within the 
population in stable phase after MI does not align well with the consensus on management 
based on individual total risk assessments.1,3,8,38 Thus, patients with the highest risk and 
greatest need for aggressive treatment within the post-MI population may not be selected for 
the most intense treatment available. Prophylactic treatment should always balance risks 
associated with the indication for treatment, potential benefits of treatment, and potential 
treatment side effects. Highly efficient but expensive drug therapies may be cost-efficient if 
provided to high-risk patients only. Potential survival benefit may outweigh potential serious 
side effects. Conversely, potential benefits of a treatment may be outweighed by the side 
effects in patients with a relatively low risk of a recurrent ASCVD event. Both under- and 
overtreatment affect cost-efficiency for the individual patient as well as society. There is 
consequently a need for improved risk prediction in stable phase post MI. 
The knowledge about how and if the traditional CV risk factors actually predict recurrent 
ASCVD events is weak.8,99 These risk factors were epidemiologically identified and 
established for primary prevention to assess the risk of a first clinical manifestation of CV 
disease.33 Therefore they cannot simply be extrapolated to apply to the population with 
established CV disease. The post-MI population is further differentiated in a high-income 
country affording the resources to provide modern health care. In theory, and logically, the 
predictive value of an untreated traditional risk factor level diminishes as an intended result of 
the risk factor modifying drugs and lifestyle interventions routinely used post-MI. If such a 
shift in relative predictive importance take place, other less established risk factors, such as 
SES, may play a larger role for risk of subsequent events in the post-MI setting. LDL-C and 
hypertension are causally linked to atherosclerosis and important to treat.38,100,101 Regardless 
of being ideal risk factors that are convenienty measured and suitable for monitoring as levels 
respond reliably to pharmacological treatment intensity, LDL-C and blood pressure levels 
may not be appropriate for secondary prevention risk assessments in the stable post-MI 
patient. 
2.7.4 Room for Improvement 
The implementation of secondary prevention according to ESC guidelines38 is evaluated 
periodically. EUROpean Action on Secondary Prevention through Intervention to Reduce 
Events (EUROASPRIRE) are cross-sectional surveys based on respondents to interviews 
conducted 6-36 months after a coronary event or intervention and a retrospective review of 
their medical records. The purpose is to chart patient CV risk factor levels and to evaluate 
whether secondary prevention management after coronary events or interventional 
procedures adheres to the guideline recommendations. EUROASPIRE was first conducted in 
1994 by inititative from the ESC, the European Atherosclerosis Society, and the European 
Society of Hypertension and has since been repeated four times. The report of 
EUROASPIRE IV11 was discouraging. 7,998 patients from 24 European countries were 
interviewed between 6 and 36 months after a coronary event or intervention. Among these, 
49% of smokers continued and only 19% of them had been advised behavioral intervention 
 
 15 
or pharmacological support. Obesity was reported in 38% and diabetes by 27%. 60% reported 
physical inactivity, 51% were advised participation in a cardiac rehabilitation program but 
only 41% attended. Guideline target levels for blood pressure and lipids was achieved in 57% 
and 19%, respectively.  
In absence of a method for risk stratification post-MI, therapy should at least be provided to 
each generic post-MI patient as recommended by current guidelines. Whether the 1-year 
survivors after MI with the highest CV risk achieve targets and received recommended 
therapies to a greater or lesser extent than average is unknown.  
2.7.5 Review of Secondary Prevention Risk Prediction Studies 
The state of knowledge on CV risk factors with predictive importance in secondary 
prevention after MI for recurrent ASCVD events was assessed in preparation for the half-
time seminar of this thesis in November 2018. The PubMed and Web of Science databases 
were searched using combinations of relevant Medical Subject Headings (MeSH) keywords 
for secondary prevention risk prediction studies published between 2001 and 2018. Citations 
within retrieved articles were followed for additional references. Study samples, time 
between indexing event, inclusion and assessment, methods of predictor selection, and time-
to-event predicted varied considerably. For sensible comparison with the post-MI cohort of 
this thesis, studies on populations with an indexing coronary event or procedure that were 
estimating risk for an ASCVD event outcome were selected for evaluation (n=8). 
Table 1 reports the qualifying predictors of each secondary prevention risk prediction study 
by CV risk factors recommended management according to the major international guidelines 
on CV prevention.3,38 Notably, neither hypertension nor LDL-C were clearly predictive of 
recurrent CV events in secondary prevention after a coronary event or procedure. Conversely, 
conformity was observed between guidelines and assessed predictive values for risk factors 
age, smoking status, diabetes, and previous manifestations of ASCVD across selected studies. 
Availability of candidate predictors were limitations of both trial- and registry-based samples. 
For instance, very few studies considered psychosocial factors or cardiac rehabilitation as 
candidate predictors. None of the selected secondary prevention prediction studies included 
participation in cardiac rehabilitation, a well-documented risk-modifying intervention after 




Table 1. Qualifying predictors of secondary prevention prediction/risk score 


























































Trial population x x    x x  
N 8557 5654 8144 912 4858 8598 13163 15770 
External validation (x) ? - x - x x x 
No. of predictors 10 5 11 4 10 9 7 12 
Age         
Sex         
SES/pychosoc         
Smoking         
Alcohol         
Diet         
Physical Inactivity         
Over-/Underweight         
Hypertension         
Diabetes         
Dyslipidemia         
LDL-C         
Depression, Anxiety         
Family History         
Manifest ASCVD         
Acetylsalicylic acid         
Beta blockers         
RAAS inhibitors         
Statins         
Cardiac Rehabilitation         
Abbreviations: SES, socioeconomic status; LDL-C, low density lipoprotein cholesterol; ASCVD, atherosclerotic 
cardiovascular disease; RAAS, Renin-angiotensin-aldosterone system. 
Green indicates a risk factor qualified to to the final prediction model 
Orange indicates a risk factor may have qualified statistically, but was not chosen to the final prediction model or did not 
qualify statistically but was chosen. 
Red indicates a risk factor assessd that did not qualify statstically as a predictor and was not included in the final 
prediction model. 
Blank indicates a risk factor was not considered a potential predictor in the analysis. 
2.8 RISK FACTORS WITH POTENTIAL IMPORTANCE IN SECONDARY 
PREVENTION 
The transition from primary to secondary prevention does not reset the abundance of 
evidence for, sometimes causal, associations between the traditional CV risk factors and 
further progression of atherosclerosis. These risk factor need aggressive management also in 
secondary prevention. Nonetheless, the CV risk factors currently used in secondary 
prevention risk assessment need reevaluation. SES may better separate high- from low-risk 
individuals within the secondary prevention population after MI. 
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2.8.1 LDL-C – the Dominant Established Risk Factor 
Evidence of efficient prevention of incident fatal and nonfatal ASCVD events from 
cholesterol lowering was first shown in 1994 by the Scandinavian Simvastatin Survival Study 
(4S)111 Since then, new generations of statins have been developed, each more potent than the 
former with regards to both lipid lowering effect and reduction of CV events.112 Several 
hypotheses on the underlying mechanisms through which lipid lowering therapies act are still 
debated.  
The statin hypothesis suggest what the 4S Study and subsequent major statin trials were 
evident of; that CV risk reduction is proportional to statin therapy intensity. Proponents of the 
LDL-C hypothesis instead suggest that it is the achieved lower level of LDL-C that exerts an 
effect proportional to CV risk reduction. The LDL-C hypothesis has covered ground in recent 
years alongside emerging confirmatory evidence of a causal role of LDL-C for 
atherosclerosis based on genetic, epidemiological, and clinical studies.81 Some advocates 
even suggest that effective LDL-C lowering alone may eliminate coronary disease.32 With 
stronger focus on LDL-C levels in CV care overall, LDL-C has also gained a status of 
importance for residual CV risk assessment post-MI and for decisions on continued treatment 
intensity. LDL-C has become a surrogate marker of adverse outcomes. Recent examples are 
the first trials targeting further reduction of LDL-C on top of statins using monoclonal 
antibodies, proprotein convertase subtilisin/kexin type 9 (PCSK9)-inhibitors. In FOURIER 
and ODYSSEY-OUTCOMES113,114, LDL-C levels were reduced by half on top of high-
intensity statin therapy but neither provided evidence of mortality benefits in the treatment 
arm. Potential benefical pleiotropic effects from statins115, such as an anti-inflammatory116, 
may have been underestimated.  
The inflammatory hypothesis of atherosclerosis is far from rejected. Contrary, findings from 
the 2017 CANTOS-trial rather sparked interest. Another monoclonal antibody was evaluated 
in this trial. Canakinumab neutralizes interleukin-1ß of the innate immunity system and 
treatment efficiently reduced recurrent ASCVD events in patients with recent MI without 
interference of lipid levels.116 Similarily, the anti-inflammatory mechanisms of a substance 
used by humans for millennia, colchicine117, improve CV outcomes in patients with acute MI 
according to findings of a recent trial.118 Importantly, a 2020 randomized clinical trial 
evaluating low-dose colchicine treatment among patients in stable phase secondary 
prevention after MI was also efficient for risk of recurrent ASCVD.119,120. 
Lipid level treatment targets have been used in secondary prevention of manifest ASCVD 
since the 1990s.121 Initial focus on total cholesterol levels transitioned via multiple measures 
of dyslipidemia to LDL-C in the early 2000s.122 Since then, the LDL-C target level has 
periodically been lowered in guideline recommendations.123-125 To date, no trial has evaluated 
two LDL-C target levels against each other for evidence of morbidity or mortality benefit. 
The recommended LDL-C target levels used in clinical practice are arbitrary and based on 
post-hoc analyses of clinical trials and can therefore be questioned.126 
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2.8.2 Socioeconomic Status – Amplified Importance in Secondary 
Prevention? 
2.8.2.1 Why SES may be an important risk factor in secondary prevention after MI 
The mutual prognostic significance among established CV risk factors may not remain the 
same before and after initiation of routine secondary prevention therapy. Increasingly more 
aggressive management of a risk factor, such as LDL-C, will lower the on-treatment risk 
factor level. Hypothetically, if all measurable traditional CV risk factors in all individuals of 
the post-MI population were treated to normal levels, the risk for recurrent ASCVD events 
would decrease but still remain elevated compared to risk for incident ASCVD in the general 
population. Lowering CV risk factor levels may also reduce the residual prognostic 
importance of the risk factors. In this hypothetical framework, the prognostic importance of 
unmodified risk factors would increase relative to the modified traditional CV risk factors.  
SES has consistently been associated with incident MI in primary prevention, independent of 
prevalence of traditional risk factors. SES has been put forward as an emerging non-
traditional CV risk factor and suggested to be incorporated into primary prevention risk score 
algorithms.13 The 2012 Joint ESC Guideline on CV disease prevention did describe SES as a 
risk factor.123 The current 2016 version of the guideline categorizes SES to “other risk 
markers” and is highlighted as a risk modifier with potential to reclassify borderline low total 
risk estimated with ESC SCORE.38 
2.8.2.2 Adherence 
A major problem for health care in general is that adherence to drug treatment among patients 
with chronic diseases is approximately 50%.127,128 Patient adherence is a major hurdle to 
overcome for improvement of secondary prevention after MI.129 Many factors that affect 
adherence negatively have been identified and include the need of breaking long-standing 
habits, treatment of asymptomatic conditions, complex drug regimens, total number of 
pills130, long duration of treatment, actual or plausible treatment side effects, low health 
literacy, lack of involvement in the treatment-decision process, lack of transportation, lack of 
social support, high medical costs, and more.129,131  
The expectations on post-MI patients are very high with regards to adherence to the 
recommendations provided with CV prevention guidelines. ASCVD is a disease of the 
elderly and key components of secondary prevention is usually complete lifestyle change 
regarding diet, physical activity, alcohol and tobacco. Furthermore, risk factor-modification 
requires multiple pills daily that have potential side effects. Most interventions are intended 
for life and target asymptomatic risk factors. Although Swedish health care is heavily 
subventioned for the individual, secondary prevention is not free of charge.  
Hence, secondary prevention after MI is a textbook example of a setting with prerequisites 
for poor population adherence. Many reasons for non-adherence correlate to SES and the 
association has been demonstrated.46,132,133  
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2.9 BACKGROUND SUMMARY 
MIs are common and major contributors to overall morbidity and mortality in Sweden and 
globally. Several decades of considerable research efforts has improved knowledge about the 
underlying pathological processes, atherosclerosis, and risk factors associated with 
progression. Efficient therapies have been developed for risk factor modification as well as 
management in the acute phase of an MI. As a result, MI mortality has steadily declined over 
the past quarter of a century in Sweden and other high-income countries while the population 
with manifest ASCVD grows larger. 
A less extensive scientific literature exists about the secondary prevention population in 
stable phase after MI. A strategy of extrapolating the risk factors, methods, and priorities of 
primary prevention to the secondary prevention population is ongoing. However, this practice 
is failing in spite of regular introduction of ever more efficient risk-factor modifying 
therapies. The continuous decline of 1-year mortality seem to be reaching a plateau.60 Current 
approaches to secondary prevention risk factor management performs poorly with regards to 
achievements of stipulated treatment targets. Moreover, existing reports on the predictive 
values of the established CV risk factors in this population are inconsistent. 
The issue of adherence may contribute to the poor performance of secondary prevention in 
addition to deficient understanding about the relative risk contribution from risk factors in the 
secondary prevention setting. SES may be considered a “cause of the causes”. That is, a 
determinant of health through which the established CV risk factors develop. There are strong 
and well established links between SES and adherence, SES and traditional CV risk factors, 
and between SES and CV outcomes. Hence, SES may be an underestimated risk factor in 
secondary prevention after MI. Relatively well-managed traditional CV risk factors such as 
LDL-C may receive disproportionate focus. Meanwhile, risk factors that are managed by 
non-physicians, including physical activity and other behavioral interventions, may also be 
underestimated. 
The studies of this thesis targeted the knowledge gap about risk factors in secondary 
prevention after MI and the role of SES in this population. Through improved knowledge on 
these areas, high-risk individuals within a large patient population may be better identified for 
more individualized and risk-based treatment intensity. Moreover, health care costs-





3 RESEARCH AIMS 
The overall aim of this thesis was to improve the knowledge about risk factors of importance 
in secondary prevention among patients in stable phase after myocardial infarction, with 
special focus on socioeconomic status and prognosis.  
Specifically, the aims were: 
§ To assess the association between both established risk factors, achieved blood lipid 
levels, as well as a less established risk factor, socioeconomic status, and recurrent 
major atherosclerotic cardiovascular disease events. 
 
§ To study underlying mechanisms of risk, whether socioeconomic disparities within 
secondary prevention were modifiable risk mediators for subsequent cardiovascular 
events. 
 
§ To elucidate ways in which socioeconomic status is associated with available 






4 MATERIALS AND METHODS 
A large nationwide population of MI survivors was studied in retrospective cohort studies 
using prospectively collected data. The studies were made possible by the existence of 
multiple Swedish national registries and the means to link the wealth of individual-level data 
they collect. 
4.1 DATA SOURCES 
Several government agencies collect a variety of individual-level data in Sweden for purposes 
including national official statistics and taxation. The Swedish Tax Agency (Skatteverket) 
manages the Swedish Population Register which gathers birth and death certificate data. In 
1947, Sweden was the first country in the world to assign each and every person residing for 
1 year or more in the country a unique personal identification number to facilitate the tasks of 
the Swedish Tax Agency. This unique 10-digit number enables for linkage between national 
registries.134 Sweden also boasts a strong tradition of numerous certified National Quality 
Registries that are sanctioned and partially financed by the state.135,136 National Quality 
Registries collect individual-level data concerning a health issue with the purpose of 
nationwide health care development including the opportunity of continuous benchmarking 
between hospitals, and ultimately to improve the outcomes for patients. Registry-based 
research in Sweden requires approval by Swedish Research Ethics Committees before access 
to specified data requests may be granted by the central personal data controller of the 
registry.136 Multiple registries were used for the studies of this thesis. The National Board of 
Health and Welfare collected each dataset, linked the datasets using the personal 
identification number, and pseudonymized the data before it was handed over to the 
researchers for further statistical management and merging. 
4.1.1 SWEDEHEART 
The National Quality Registry for cardiac care is Swedish Web-system for Enhancement and 
Development of Evidence-based care in Heart disease Evaluated According to 
Recommended Therapies (SWEDEHEART) which is managed by Uppsala Clinical Research 
Center (UCR). As a National Quality Registry, Swedish law sanctions patient registration 
without active consent but patients need to be informed about registration and their right to 
opt-out or to have their data erased at any time upon request. Opt-out is however extremely 
rare. Launched in 2009, SWEDEHEART is a registry for Swedish cardiac care in its entirety 
with direct online data entry by local health care professionals. The web-based case report of 
each patient provides a convenience when patient are transfered between units and hospitals. 
Hundreds of variables on each individual with MI may be collected to SWEDEHEART 
throughout the course of care.137 Biannual monitoring visits to each Swedish hospital is 
performed to ensure data consistency through random sample comparison between registry 
data and hospital health records. A recent application of SWEDEHEART and UCR has 
become to serve as a platform for registry-based randomized clinical trials (RRCTs).138 The 




Registry of Information and Knowledge about Swedish Heart Intensive care Admission 
(RIKS-HIA), the initial care sub-registry of SWEDEHEART, was initiated in 1991, rapidly 
spread to new hospitals, and developed into a certified National Quality Registry in 1995. 
Since 2008, all cardiac care hospitals throughout Sweden reports to RIKS-HIA.137 Detailed 
clinical data on previous risk factors and comorbidities, from admission, during inpatient 
care, and at hospital discharge are collected. In 2013, coverage was 92% of all patients aged 
<80 years who were hospitalized with MI (according to the 10th edition of the international 
classification of diseases, code I21) as the main diagnosis.10 
4.1.1.2 SEPHIA 
SEcondary Prevention after Heart Intensive care Admission (SEPHIA) was founded in 2005 
as a secondary prevention complement to RIKS-HIA. Since start, the purpose has been to 
improve the treatment targets of secondary prevention after MI in Sweden through systematic 
monitoring of risk factor levels, provided care, and outcomes including risk factor target 
achievements.137 Data was collected to SEPHIA at routine clinical revisits, preferably 6-10 
weeks and 12-14 months after MI, in this thesis referred to as the 2-month and 1-year revisits. 
If a physical visit was not feasible, SEPHIA data collection was also possible via phone call 
and supplementary biometric and biochemical data acquired through primary health care 
visits at the recidency of the study participant. A SEPHIA registration was trigged by default 
for all patients aged ≤75 years discharged from a coronary care unit with a MI (type 1) 
diagnoisis in whom the RIKS-HIA-report is completed. It was optional for cardiac care 
centers to register older age groups. Data was collected on risk factor levels based on 
biometrics, blood samples, lifestyle factors, and questionaire scores, patient reported 
symptoms and quality of life, as well as interventions and drug therapies that were ongoing, 
planned, quit or completed. If a second MI occurred in an individual within the first year, it 
was registered as a readmission, not a new SEPHIA registration. 70 out of 72 (97%) cardiac 
care units in the country were reporting to SEPHIA by 2014. Completeness was 81% of 
eligible patients younger than 75 years attending the 1-year visit after hospital care for MI. 
Participants lost to follow-up were at the group-level more likely to have a history of ASCVD 
(and secondary prevention efforts) than SEPHIA-attendees. Agreement between registry and 
health record data was around 95%.10,135  
4.1.1.3 SCAAR 
Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was founded in 1998 by 
merging national registries on angioplasty and angiography and was incorporated into 
SWEDEHEART in 2008.137 SCAAR is the sub-registry on procedual interventions and 
collects data related to angiographies and PCIs. In 2014, 26 centres throughout Sweden 
performed coronary angiography and PCI.10 
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4.1.2 Statistics Sweden 
Statistics Sweden (Statistiska centralbyrån, SCB) is the government agency responsible for 
the official statistics of Sweden including demographics. One of the registries managed is the 
database Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA). In the LISA database, labour market, educational, and social sector data is collected 
annualy on all citizens aged over 16 years.139  
4.1.3 The National Board of Health and Welfare 
The National Board of Health and Welfare (Socialstyrelsen, SoS), a government agency 
under the Department of Social Affairs, is responsible for collecting and managing national 
health data including births, deaths, hospital discharges, and prescribed drugs.140 The 
following national health data registries were used in this thesis:  
4.1.3.1 The National Patient Register 
Since 1987, the National Board of Health and Welfare gathers data on inpatient diagnoses 
from all hospitals throughout Sweden. Diagnoses are coded according to the international 
classification of disorders (ICD). Since 2001, diagnoses registered at public and private 
outpatient care facilities, except primary care, were added to the registry. The National 
Inpatient Register is the subregistry covering diagnoses of patients hospitalized and 
discharged. Coverage for inpatient care is almost 100% complete.141 
4.1.3.2 The Cause of Death Register 
In Sweden, all causes of all deaths in the population has been recorded since 1911. The Cause 
of Death Register was managed by the Statistics Sweden until 1994 when responsibility was 
transfered to the National Board of Health and Welfare. Swedish law mandates that certified 
deaths are reported to the Swedish Tax Agency and that a separate cause of death-report is 
sent within three weeks to the National Board of Health and Welfare. In case a cause of death 
cannot be establish with reasonable certainty, autopsy is warrented. Causes of deaths reported 
are coded according to the International Classification of Diseases (ICD) together with 
personal identification data, relevant dates, geographic location, and underlying comorbidities 
and diseases contributing to death. Coverage of deaths is near complete and even though rates 
of autopsies have declined in recent year, 96% of deaths have a sufficiently specified 
underlying cause recorded.142 
4.1.3.3 The Prescribed Drug Register 
All drugs prescribed and dispensed at any pharmacy throughout Sweden is registered in the 
national Prescribed Drug Register since 2005. Data collected includes patient identification 
data, brand name and pharmacological substance categorized according to Anatomical 
Therapeutic Chemical (ATC) classification system, formulation, quantity, intended dosage 
regimen, and relevant dates.143 Data on over-the-counter drugs and drugs dispensed to 




Eligible study cohort participants of this thesis were registrered in SWEDEHART at the 2-
month or 1-year revisit between 1 January 2005 and 31 December 2013. The optionally 
higher age limit than mandatory for inclusion post-MI in the registry allowed for setting the 
upper age limit to 76 years or younger and the specified time intevals between index MI and 
the revisits were expanded to 4-14 weeks and 11-15 months, respectively. To study a cohort 
naïve of previous exposure to cardiovascular secondary prevention, eligible participants with 
previous MI, stroke, PCI or stroke were excluded.  
In Study I, III, and V, only participants surviving to attend and be registered at the 1-year 
revisit were included for a study samples in stable phase of coronary heart disease. Baseline 
visits prior to January 1, 2006 were excluded for bias-minimized data on the primary 
indicator of SES, disposable income. In Study I, a lower age limit of 40 years was used. 
In Study II, the 2-month visit was used as baseline. Two months is a sufficient time period 
after initiation of statin therapy to evaluate treatment effect on lipid levels144 and for decisions 
on continued lipid management in clinical practice.  
In Study IV, the study question required a cohort more representative of the population 
eligible for clinical trial participation after MI. Therefore, patients with previous history of 
nonfatal ASCVD or invasive cardiac interventions who survived until the 1-year visit were 
included. Only patients attending their revisit from 2008 were included as study participants 
because of when the exposure variable was introduced in SWEDEHEART. 
4.3 EXPOSURES 
4.3.1 Socioeconomic Status 
The relative importance of different indicators of SES vary with the population and outcome 
studied. Therefore, multiple indicators were chosen and mutually adjusted. Besides gaining 
knowledge on their relative importance in secondary prevention after MI, an intent was to 
improve chances of findings that would be comparable to similar studies. Two well 
established indicators of SES in CV research, levels of income and education44, were chosen 
in this thesis. Use of novel or less established indicators of SES are also recommended.44 
Owing to the importance of social support for CV disease, marital status was added as an 
indicator of SES.  
4.3.1.1 Income level 
The mean disposable income per household consumption unit was chosen to measure 
disposable income level. This measure accounts for each study participant’s household size 
and composition. It is calculated by dividing the sum of the disposable income of all family 
members with the total household consumption weight (the sum of weighted consumption by 
age of each family member).139 Data acquired in the year preceding that of the index MI was 
used for income levels that were unaffected by sick leave due to the MI. The income levels 
 
 27 
were categorized by quintiles into calendar year-specific fifths to correct for inflation 
throughout study years, because of a proportionally higher SES in the initial years after 
SWEDEHEARTs secondary prevention sub-registry was founded, and for more intuitive and 
useful comparison than between figures of the actual earning. Due to lower median income 
among women than among men, the proportion of women classified to low SES by proxy of 
disposable income quintile was disproportional. Therefore, in Study III and V, the income 
quintiles were categorized into quintiles for men and women separately and then combined 
for gender- and calendar year-specific income levels. 
4.3.1.2 Educational level 
The highest educational attainment at the baseline visit was chosen and categorized according 
to thresholds of the current educational system in Sweden: ≤9 years, 10-12 years, and >12 
years equivalent of compulsory education (primary and lower secondary education), upper 
secondary education, and ≥1 semester of post-secondary education including postgraduate 
education, respectively. 
4.3.1.3 Marital status 
Marital status at the baseline visit was categorized as married (including registered 
partnership) and not married (further subcategorized into unmarried, divorced, and widowed). 
4.3.2 Blood Lipid Levels 
In Study II, levels of total cholesterol, LDL-C, HDL-C, and triglycerides were used as 
measures of exposure. Lipid levels registered in the secondary prevention sub-registry of 
SWEDEHEART were from blood samples drawn in close proximity (±2 weeks) to the first 
revisit after MI. The principal method for obtaining levels of LDL-C was by calculation using 
the Friedewald forumla: LDL-C = total cholesterol – (triglycerides x 0.45) – HDL-C in 
millimoles per liter.145 In cases where use of the Friedewald formula was invalid, for example 
if the level of triglycerides was higher than 4.5 mmol/L, or if data on non-LDL-C lipid 
fractions were unavailable, a direct measurement of LDL-C was used if available. Each lipid 
fraction was categorized into quintiles. LDL-C was also categorized by thresholds used in 
guidelines and clinical practice124: <1.8 mmol/L, 1.8 to <2.6 mmol/L, 2.6 to <4.0 mmol/L, 
and ≥4.0 mmol/L. 
4.3.3 Clinical Trial Participations 
Exposure of Study IV was clinical trial participation (no, yes). The original SWEDEHEART 
variable was introduced in 2007 for data collection at the 2-month and 1-year revisits and 





4.4.1 Recurrent Atherosclerotic Cardiovascular Disease Events 
In 2013, the ACC/AHA replaced the Framingham Risk Score with the New Pooled Cohort 
Risk Equations as the recommended primary prevention risk algorithm. As a consequence, 
the predicted outcome changed from composite MI or coronary heart disease death to a new 
primary composite outcome, “first hard ASCVD event” which was defined as first 
occurrence of nonfatal MI, coronary heart disease death, or fatal or nonfatal stroke. The new 
composite outcome was chosen because of greater clinical relevance for patients and 
providers.3  
The primary outcome in Study I, II, IV, and V, rASCVD, mimics the outcome of the New 
Pooled Cohort Risk Equations and the prefix r indicates “first recurrent”. Apart from clinical 
relevance of chosen events, rASCVD also resembles the composite outcomes used in many 
outcomes trials that shape evidence and guideline recommendations after MI. Events were 
defined as nonfatal MI, coronary heart disease death, fatal or nonfatal ischemic stroke. Codes 
for corresponding main discharge and death diagnoses according to ICD-10 were collected 
from the National Inpatient and Cause of Death registries. (Table 2) Events of rASCVD were 
collected from study baseline visit until the first event within the follow-up time frame or 
censoring due to study end or death from other cause.  
Table 2. Definition of ASCVD 
Outcomes ICD-10 code Registry 
ASCVD 
Nonfatal MI  I210-I214 & I219, I220-221, I228-I229 Inpatient 
CHD Death 
Fatal MI I210-I214 & I219, I220-221, I228-I229 Cause of Death 
Sudden 
Cardiac Death I461, I469 Cause of Death 
Fatal Ischemic 
stroke  I630-I635, I638-I639 Cause of Death 
Nonfatal Ischemic 
Stroke  I630-I635, I638-I639 Inpatient 
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; ICD-10, international classification of diseases, 10th edition; 
MI, myocardial infarction; CHD, coronary heart disease. 
4.4.2 Secondary Outcomes 
In Studies I and II, secondary outcomes were fatal or nonfatal MI (ICD-10: I21.0-4, 9 and 
I22.0-1, 8-9), fatal or nonfatal ischemic stroke (ICD-10: I63.0-9), and all cause death. In 




4.4.3 Secondary Prevention Activities and Treatment Target Achievements 
In Study III, relevant major CV prevention guidelines were consulted for the selection of 
study outcomes.8,38 SWEDEHEART variables were available for most risk factor targets and 
secondary prevention activities recommended while some were not. For example, no data 
was available to assess the targeted lifestyle change to a mediterranean diet and no variable 
existed for administration of annual influenza vaccination.  
Risk factor target outcomes were assessed at the 1-year revisit and included achievement of: 
§ Smoking cessation. Estimated among study participants that were current smokers at 
admission for the index MI. 
§ Physical activity. Based on self-reported activity on leisure time during the week prior 
to the revisit. Defined by the achievement of the recommended minimum activity 
level of at least 5 sessions a week of moderate exertions lasting 30 minutes or more. 
§ LDL-C. Achievement was defined in relation to target levels applicable in Sweden 
during the study period: <2.5 mmol/L before 2012 and <1.8 mmol/L after 2012. 
§ Blood pressure. Thresholds were set for systolic blood pressure to <140 mmHg and 
for diastolic blood pressure to <90 mmHg. 
§ Glycated Hemoglobin (HbA1c). A threshold was set at <53 mmol/mol and assessed 
among study participants with a diabetes diagnosis at the index MI. 
Secondary prevention activities utilized throughout the first year after MI included: 
§ Participation in programs within comprehensive cardiac rehabilitation registered at 
either the first or second follow-up visit: 
- Physical training program. Defined as structured individualized physical 
exercise including both cardiorespiratory and weight training led by a 
physiotherapist for 3 months or more. 
- Patient educational group sessions (Hjärtskola). Interactive program during 
which MI patients and their family members are educated on coronary artery 
disease and consequences, CV risk factors, healthy diet, tobacco use, 
psychosocial factors, physical activity and exercise for risk factor control and 
drug therapies. Information routinely provided during inpatient care, at 
discharge and at revisits not included. 
- Stress management group session. Structured behavioural program led by a 
person with competence in techniques for stress relief. Estimated in study 
participants with self reported symptoms of anxiety or depression screened for 
at the 2-month visit using the EQ-5D standardized questionaire.146 
- Smoking cessation program. Structured program or counseling arranged by 
the hospital, primary care or private initiatives. Estimated in study participants 
smoking at admission for the index MI. 
- Dietary course. Program on healthy dietary habits intended for patients with 
coronary disease.  
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§ Monitoring of risk factor levels: 
- Glycated Hemoglobin (HbA1c) monitoring. Monitoring was considered 
adequate in study participants with diagnosed diabetes if there were ≥2 
measurements recorded out of the three patient-health care interactions at 
discharge from initial care, and the two revisits. 
- Lipid level monitoring. Adequate monitoring was set to registration of a blood 
sample drawn for a lipid panel including total cholesterol, LDL-C, HDL-C, 
and triglycerides at ≥1 of the two revisits. 
- Statin therapy intensification. Whether statin therapy was intensified between 
the two follow-up visits was estimated using data from the National 
Prescribed Drugs Register on the dosages and statin-types of the claimed 
statin prescriptions. Statin therapy intensity was stratified according to the 
2013 ACC/AHA Blood Cholesterol Guideline122,147 and the statin intensity 
(high, moderate, low) prescribed at each routine revisit was compared. 
§ Drug treatments initiated at discharge and persistent use at the 1-year visit: 
- Dual antiplatelet treatment. Assessed at discharge but not at the 1-year (12 to 
14-month) revisit because planned period of use was expected to be shorter 
according to guideline recommendation. 
- Acetylsalicylic acid 
- Statins 
- High-intensity statin therapy. According to the high-intensity definition of the 
2013 ACC/AHA Blood Cholesterol Guideline147 by using data from the 
National Prescribed Drug Register on statin type and dosage prescribed at 
discharge from the index MI and the 1-year revisit. 
- RAAS inhibitor. Including use of either angiotensin converting enzyme 
inhibitor or angiotensin receptor blocker. Use was assessed in study 
participants with indication for treatment including hypertension, diabetes, or 
LVEF ≤40% during initial care. 
- Beta blockers. Assessed in study participants with indication for use; 
LVEF≤40% during initial care. 
4.5 COVARIATE MANAGEMENT 
4.5.1 Clinical Data Management of Variables Used in Analyses 
A large number of clinical variables were used for cohort description and analyses in the 
studies of this thesis. The covariates included in analysis models are reported in Table 3 and 
the data definitions and management were as follows: Smoking status (current, never, or 
former defined as cessation >1 month prior) was self-reported at MI and at 2-month and 1-
year visits. Body mass index (kg/m2) was calculated by dividing weight (kg), measured at 
revisits, with height (m), measured at MI, squared and used as a continuous variable or 
categorized according to WHO thresholds (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m2). Diabetes 
(yes, no) collected at admission was defined as dietary or pharmacological treatment of the 
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disease, while variables collected at revisits were oral treatment for diabetes (yes, no) and 
insulin treatment for diabetes (yes, no) and were used separately or joined into a diabetes 
(yes, no)-variable. Hypertension (yes, no) was based drug treatment for hypertension at 
admission, or on dichotomization (systolic blood pressure ≥140 or diastolic blood pressure 
≥90 mmHg) of continuous measurements at revisits. Estimated glomerular filtration rate 
(eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation148 using serum or plasma Creatinine measured at initial care and a mean 
value if more than one data input was recorded. Unless continuous values, chronic kidney 
disease staging (>90, 60-89, 30-59, 15-29, <15 ml/min/1.73m2) thresholds were used. Heart 
failure (yes, no) was based on a previously documented left ventricular dysfunction (for 
example by echocardiography examination) at admission. Symptoms of anxiety or depression 
(yes, no) was collected at revisits, based on the EQ-5D-3L questionnaire146, and dichotomized 
by joining categories mild and tangible as affirmative. Hyperlipidemia (yes, no) was collected 
at MI admission and indicated ongoing drug treatment. Total cholesterol, LDL-C, HDL-C, 
and triglycerides were continuous measurements in mmol/L. Previous stroke, MI, PCI, and 
CABG were dichotomous variables collected during initial care. Peripheral artery disease 
(yes, no) was created using the National Inpatient Register by combining ICD-10 codes I702, 
I702A, I702C, I702X, I739, and I739B diagnosed prior to the 2-month revisit to match the 
definition used in the TRA2°P-TIMI50-trial.108 Main complaint (chest pain, other) at MI 
admission was dichotomized by joining dyspnea, cardiac arrest, and other primary presenting 
symptoms. ECG ST deviation (STEMI vs. NSTEMI) was created using a variable on MI type 
(STEMI vs. NSTEMI) determined at coronary care unit discharge using formal criteria and 
clinical judgement. In cases where the discharge infarction type data was missing, available 
admission ECG data on ST deviation for STEMI (defined as ST elevation of (i) ≥1 mV 
amplitude in leads I, II, III, aVF, aVL, V5 and V6 or (ii) ≥2 mm in leads V1, V2, V3 and V4, 
in ≥2 adjacent leads), NSTEMI (defined as 0,05 mV ST depression in ≥2 adjacent leads) or 
QRS annotation of pathological Q-waves (defined as (i) ≥30 ms duration and (ii) a 25% R/Q-
ratio) or left bundle branch block (defined as (i) QRS duration >120 ms (ii) monophase R-
wave in leads I, V5, and V6, (iii) absent Q-waves in leads V5 and V6) was used. ECG rhythm 
(sinus, non-sinus) collected during initial care and at the 1-year revisit were used with atrial 
flutter/atrial fibrillation and other rhythms joined to the non-sinus category. Angiographic 
findings (myocardial infarction with non-obstructive coronary arteries, 1-vessel, 2-vessel, 3-
vessel or left main disease) was a created by re-categorizing the more detailed original 
variable on significant lesions and their location as assessed by the angiographer. Troponin 
max (quintiles) was created using data on cardiac injury biomarker type (troponin T, troponin 
I, or high-sensitivity troponin T) and biomarker maximum levels (µg/L, µg/L or ng/L). The 
maximum troponin levels were categorized into quintiles by biomarker type and the highest 
biomarker quintile measurement of a study participant was selected. LVEF (≥50%, 30-49%, 
<30%) or (≥50%, <40-49%, <40%) categorizations were used for assessments obtained 
during initial care. PCI if angiographic pathology (yes, no) was created by dichotomizing the 
angiographic findings-variable and a variable on types of PCIs performed, and then 
combining the two. Dual antiplatelet therapy (yes, no) was defined as simultaneous use of  
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Table 3. Covariates included in analyses by thesis study 
 Study I Study II Study III Study IV Study V 
Age C C/P C C C 
Gender C C C C C 
Calendar year of baseline visit C C C C C 
Income level E  E C E 
Educational level E  (E) C (E) 
Marital status E  (E) C (E) 
TRADITIONAL RISK FACTORS S2 S1  S2 MI 
Smoking status C P  C M 
Body mass index C   C M 
Diabetes (dietary, oral or insulin treatment) C P  C M 
Hypertension treatment at MI C    M 
Systolic blood pressure C  [O] C  
Glomerular filtration rate at MI C P  C M 
History of congestive heart failure at MI  P   M 
Symptom of anxiety or depression at S1    C  
Hyperlipidemia treatment at MI     M 
Lipid levels S2 S1  S2  
  Total Cholesterol C E  C  
  LDL-C C E [O] C  
  HDL-C C E  C  
  Triglycerides C E  C  
Coronary disease and symptoms      
Previous MI N/A N/A N/A C N/A 
Previous stroke N/A N/A N/A C N/A 
Previous PCI N/A N/A N/A C N/A 
Prior CABG N/A N/A N/A C N/A 
Peripheral artery disease at S1  P    
Main complaint     M 
ECG ST deviation     M 
ECG rhythm MI    C   S2    C MI    M 
Angiographic findings     M 
Troponin max C    M 
Left ventricular ejection fraction C   C M 
INITIAL THERAPIES AND SECONDARY 
PREVENTION      
PCI if angiographic pathology     M 
Dual antiplatelet therapy     M 
Planned procedure     M 
Lipid profile monitoring   O  M 
Statin therapy intensification   O  M 
Screening for depression or anxiety     M 
Participation in clinical trial    E  
Cardiac rehabilitation program 
participation 
S2   S2 S1+2 
  Physical training program   O M M 
  Patient educational session (C)  O M M 
  Dietary course (C)  O M M 
  Smoking cessation program   O M M 
  Stress management group session   O M M 
Evidence-based drug therapies at S2   S1+2   
  Acetylsalicylic acid   O M M 
  Statins (C)  O M M 
  Beta blockers   O M M 
  RAAS inhibitors.   O M M 
Abbreviations: C=potential confounding factor. P=predictor according to TRS2°P prediction model.108 E=study exposure. 
M=mediator. N/A=variable used for sample exclusion criteria. O=Outcome variable. [O]= dichotomized version of variable used 
as outcome. MI=variable collected at admission or discharge from initial care of the index MI. S1=variable collected at 2-month 
visit. S2=variable collected at 1-year visit. 
Parentheses indicates that the variable was not part of the main analysis 
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acetylsalicylic acid and another antiplatelet inhibitor at discharge from initial care. Planned 
procedure (yes, no) was created from three variables indicating whether a referral was written 
by the time of initial care discharge for angiography, PCI, and sub-acute CABG, respectively. 
Screening for depression or anxiety (yes, no) was defined as yes if a data was registered and 
no if data was missing. The remainder of variables listed in Table 3 are described separately 
in the Exposures and Outcomes sections. 
4.5.2 Covariate Determination 
In all studies of this thesis, bias-minimized analysis models were built using causal diagrams, 
Directed Acyclic Graphs.149 This is a graphical method in which analytic covariates and their 
relationships are drawn according to a set of rules. Assumptions on the causal direction of 
relationships are introduced in this method. These assumptions were based on the collective 
experience of the research group from clinical work within cardiac care and registry-based 
research and literature review. The causal diagram then guide decisions on appropriate 
statistical management for bias-minimized analyses by determining measurable confounding 
and mediating factors. Age, gender, and calendar year of inclusion were potential 
confounders. That is, analytic covariates presumed to be causal in their relationship with both 
the exposure and the outcome. Circumstances considered were the upper age limit for 
SWEDEHEART inclusion, higher median age at incident ASCVD manifestations among 
women than among men, changes in clinical management taking place during the study 
period, and less representable data during initial years after the SWEDEHEART secondary 
prevention sub-registry was founded. 
In Study I, two approaches to the relationship between covariates were considered. In the 
alternative approach, both SES and CV risk factors were presumed to be determined by 
unknown and unmeasured factors in common which suggested that CV risk factors were 
confounders. In Study II, both an explanatory and a prediction modelling approach was used. 
Confounding was considered in the former while causal relationships and confounding are 
irrelevant for prediction models. In Study IV and V, groups of variables in the association 
between the respective exposure and rASCVD were determined to be confounders and 
mediators. In Study V, relationships between covariates were thoroughly rethought with 
special consideration for the risk factors and therapies recommended in major international 
guidelines and for the chronological order in which variables were collected. 
4.6 STATISTICAL ANALYSES 
Patient characteristics were reported as means and standard deviations (Study I, III, IV, V) or 
medians and interquartile ranges (Study II) for continuous data and as frequencies and 
percentages for categorical data. Differences between study group characteristics were 
compared using Student’s t-test for continuous data and chi2-test for categorical data in 
studies with predefined hypotheses on the matter (Study III and IV). 
Study II used the 2-month revisit as baseline and remaining studies identified the cohort at the 
1-year revisit. In studies with time-to-event analyses (Study I, II, IV, V), participants were 
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followed from the date of the study baseline visit until the first occurrence of an event, death 
due to other causes, or study end on December 31, 2013 (Study I and II) or on December 31, 
2018 (Study IV and V). Crude incidence rates of rASCVD by exposure category were 
calculated as the number of events per 1000 person-years and Kaplan-Meier curves were 
generated to visualize crude cumulative occurrence of rASCVD. Multivariable Cox 
proportional-hazards models were used to estimate cause-specific hazard ratios (HRs) and 
95% confidence intervals (CIs) in order to assess the associations between the study exposure 
and rASCVD. The proportional hazards assumption was assessed by means of scales of 
Schoenfeld’s residuals. No evidence of departure from this assumption was observed.  
Data management, calculations and statistical analyses were performed using Stata versions 
14, 15, and 16 (StataCorp, College Station, TX, USA) and R version 4.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria) for mediation analyses in Study V and for rendering 
Forest Plots in Studies III and IV. 
4.6.1 Study I 
Two Cox regression models were created. Model I included the three SES indicators and 
confounders sex, baseline age and calendar-year. Based on the idea of existing unknown and 
unmeasured factors that determine both SES and CV risk factors, model II was further 
adjusted for selected risk factors considered relevant in secondary prevention management 
(smoking status, diabetes, lipid levels, systolic blood pressure, hypertension treatment, body 
mass index, eGFR, LVEF, maximum troponin level, and heart rhythm). A third model, 
additionally adjusted for treatment variables collected at baseline was added by suggestion 
during the publishing review process in order to evaluate whether received secondary 
prevention treatment affected the associations between SES and rASCVD. Furthermore, 
gender subgroup analysis on the association between the SES indicators and rASCVD was 
performed. Missing data were imputed at the time of the baseline visit using last observation 
carried forward if previous measurements existed (that is, either during the 2-month revisit or 
during initial care). Remaining missing values were included in the models as a separate 
category.  
4.6.2 Study II 
In an etiological (or explanatory) modelling approach, group level associations between each 
of the lipid fractions and rASCVD were estimated using two Cox regression models. Model I 
was crude, reflecting the basis for decisions on lipid lowering therapy in clinical practice. 
Model II was bias-minimized and adjusted for age, gender, and year of the 2-month revisit. A 
prediction modelling approach was also used. Model III was built on 9 variables that had 
been identified and selected among numerous candidate clinical indicators of ASCVD risk in 
an externally validated secondary prevention risk prediction study.108,150,151 The four lipid 
fractions were then added to model III, one at a time, and the predictive performance was 
measured by calculating differences in Harrell’s C index152 with standard errors calculated 
using the jackknife estimator.153 The incremental predictive model performance from adding 
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the four lipid fractions was additionally assessed by estimating differences in integrated 
discrimination improvement (IDI) and continuous net reclassification improvement 
(cNRI).154,155 
In a sensitivity analysis, the robustness of model II findings was assessed by comparing 
estimates of the association between lipid levels and rASCVD in subgroups with and without 
high-intensity statin therapy. A second sensitivity analysis evaluated the potential 
confounding from intensification of lipid lowering therapy after the baseline visit among 
patients with high LDL-C levels. This was done by adding an adjustment factor accounting 
for any change in statin treatment intensity (none, decrease, increase) after the 2-month revisit 
to model II. In a third sensitivity analysis, HDL-C and triglycerides were both entered into 
model II in order to evaluate covariation between levels the two lipid fractions. There were 
negligible numbers of missing data for variables included in analytic models I-III and 
therefore no imputation of data was performed. 
4.6.3 Study III 
Associations with the outcomes were estimated using multivariable logistic regression 
models including the disposable income quintiles, age, sex, and calendar year of the baseline 
visit. Estimates were presented as odds ratios (ORs). Robust sandwich estimators were used 
to estimate standard errors and 95% CIs were reported. Educational level and marital status 
were added as covariates in separate analysis for estimates of associations with the outcomes 
in which SES-indicators were mutually adjusted. No missing values were imputed because of 
few missing values. The characteristics of participants with and without complete outcome 
data were reported separately. 
4.6.4 Study IV 
Univariate Poisson regression models with robust standard errors were used to estimate risk 
ratios (RRs) and 95% CIs in the associations between clinical trial participation and each 
sociodemographic, clinical and therapeutic characteristic. Clinically relevant thresholds were 
chosen for continuous outcome variables (LVEF <30%, eGFR <60 ml/min/1.73 m2, systolic 
blood pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, body mass index ≥30 
kg/m2, non-HDL-C ≥2.6 mmol/L, LDL-C ≥1.8 mmol/L, HDL-C <1.0 mmol/L in men and 
<1.2 mmol/L in women, triglycerides ≥1.7 mmol/L. SES indicators were dichotomized: 
highest vs. lowest disposable income quintile, highest vs. lowest educational level  and 
married vs. not married.  
Four multivariable Cox regression models were developed to estimate the association 
between clinical trial participation and rASCVD. Model I was adjusted for potential 
confounders (age, sex, and calendar year). Sequential models added potential risk mediators. 
Model II was further adjusted for traditional risk factors including previously ASCVD 
manifestations (previous MI, stroke, or heart surgery), LVEF and eGFR at discharge from 
initial care, and heart rhythm, smoking status, diabetes (with oral and/or insulin treatment), 
systolic blood pressure, body mass index, symptoms of anxiety or depression, and achieved 
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lipid levels (total cholesterol, LDL-C, HDL-C, and triglycerides) at the 1-year revisit. Model 
III was further adjusted for use of secondary prevention therapies including evidence-based 
drugs (acetylsalicylic acid, statins, beta blockers, and RAAS inhibitors) and participation in 
comprehensive cardiac rehabilitation (physical training program, interactive patient 
educational sessions, dietary advice course, smoking cessation program or counseling, and 
stress management group sessions). Model IV was further adjusted for SES (disposable 
income, educational level, and marital status). Missing values were included in the models as 
a separate category. 
4.6.5 Study V 
Five Cox regression models were developed. The base model included disposable income as 
proxy for SES and age, gender, and calendar year that were considered confounding factors. 
Then, clusters of covariates were added in sequential models by chronological order of 
participant exposure. Risk attenuation attributable to each added cluster was intended to be 
interpreted as a mediating effect. Clusters were (i) CV risk factor accumulated prior to the 
index MI, (ii) measures of MI presentation and severity, (iii) initial therapies including 
procedural interventions and discharge drugs, and (iv) secondary prevention utilization 
including comprehensive cardiac rehabilitation participation, lipid management, screening for 
anxiety or depression during follow-up, and evidence-based drug therapies used at the 1-year 
revisit. 
Risk mediation was additionally assessed on time-to-event data to allow for mathematically 
consistent interpretation of causal mediation.156,157 For this analysis, four potential mediators 
were selected: risk profile through the metabolic syndrome, participation in physical training 
program, participation in patient educational sessions, and optimal statin management (statin 
intensity increase during first year after MI or high-intensity statin therapy at the 1-year 
revisit). Estimates of proportional causal natural indirect direct (NIE), i.e. mediated through a 
potential mediator, and natural direct effects (NDE) between the highest and lowest income 
quintile on rASCVD were calculated for selected potential mediators. A Cox regression base 
model was used for the primary outcome and logistic regression models were used for the 
selected potential mediators. The proportion of the total excess probability attributed to the 
NIE for a potential mediator was calculated. 95% bootstrap intervals based on 1000 
resamplings were calculated around the estimate. 
In a sensitivity analysis assessing the robustness of using disposable income as proxy for 
SES, three sequential Cox regression models were repeated adding educational level and 
marital status to the models for estimates of the association with rASCVD for mutually 
adjusted indicators of SES. For variables with higher percentages of missing values (body 
mass index, admission ECG ST-deviation, angiographic findings, maximum troponin level, 
and LVEF), missing values were included in the models as a separate category and this 
imputation strategy was evaluated in a complete case analysis. 
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4.7 ETHICAL CONSIDERATIONS 
The Helsinki declaration is a set of ethical principles for medical research involving human 
subjects that was first adopted by the World Medical Association General Assembly in 
1964.158 As required, studies of this thesis were approved by a Research Ethics Committee, 
the Ethical Review Board in Stockholm.  
Focusing on SES, an overall theme relates to the first article of the United Nations declaration 
on human rights adopted in 194854, which reads: “All human beings are born free and equal 
in dignity and rights. They are endowed with reason and conscience and should act towards 
one another in a spirit of brotherhood.” Acknowledging the existence of widespread 
disparities in secondary prevention after MI, in a country with universal health care, provides 
incentives for further exploration on underlying causal mechanisms and study on efficient 
measures to improve health equity.  
According to the Helsinki declaration, the forseeable benefits of conducting a study must 
outweigh risks and burdens to the research subjects. From this ethical aspect, ASCVD is a 
chronic disease and the most common cause of mortality and morbidity both in Sweden and 
globally. New knowledge based on relevant hypotheses, sound scientific methods, and high 
quality data have the potential for real-world improvements. However, the study participants 
are unlikely to benefit directly from study findings. This thesis was registry-based in its 
entirety. Although SWEDEHEART data is collected prospectively, the design of the studies 
of this thesis were retrospective. Consequently, many participants were not even alive by the 
time of data analyses. Unlike experimental study designs, observational studies poses no risk 
of physical harm for participants.  
General principles of the Helsinki declaration state that the well-being, rights, dignity, 
integrity, confidentiality of personal information, and privacy of the individual research 
subjects must always exceed the interests and goals of science and society. Several legal 
ethical measures were undertaken in addition to applications for ethical approvals; A 
confidentiality agreement was established between Karolinska Institutet and agencies that 
manage the National Registries used. The dataset used for this thesis was created in 
compliance with the Personal Data Act (personuppgiftslagen). Before the data was made 
available to the researchers, the National Board of Health and Welfare had pseudonymized 
the linked dataset. A deciphering key was kept at the government agency for a predetermined 
time period until destruction. During this time period, requests for complementary data 
extracts were only considered after amendment approval by Regional Ethical Review Boards. 
Thereby, the research group were never directly handling sensitive information that was 
traceable to individual identities. Furthermore, the cohort size was sufficiently large to make 
identification through combination of individual-level data highly unlikely. 
Infringement of personal integrity is possible in a retrospective registry-based study. The 
degree of such violations are dependent on subjective sense of harm as well as more objective 
plausible or actual consequences. The individual-level data used in this thesis not only 
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contains extensive sensitive information on personal health but also on socioeconomic 
indicators. If all data used in this thesis was made freely available, in particular if identities 
were deciphered, misuse could take many forms. For instance, personal health data on 
morbidities and risk factors for morbidities and preterm death as well as personal data on SES 
could lead to discrimination. Assumptions on risk derived from personal health data have 
major plausible consequences for insurance policies, employment and career opportunities. 
Informed consent is another ethical cornerstone of the Helsinki declaration. Swedish registry-
based research is typically approved by Swedish Research Ethics Committees even though it 
is debatable whether all requirements for informed consent are met. The first article of the 
Helsinki declaration states that the declaration applies to medical research involving 
“identifiable human material and data”. Apart from the initial collection of data to 
SWEDEHEART, one may claim that the researchers involved in this thesis project only 
access pseudonymized data. However, a deciphering key does exist. One may question what 
measures have been taken to keep such deciphering keys safely stored away from 
unauthorized access considering the continuous digitalization of society and increasing 
demands for data safety. In theory, the mere existence of a deciphering key for our 
pseudonymized dataset in fact means our data is traceable to individuals, i.e. identifiable 
human data, and the Helsinki declaration should apply. The Helsinki declaration further 
declares that there may be “exceptional situations”, where informed consent is “impossible or 
impracticable to obtain”, where research may be conducted if a Research Ethics Committee 
first reviews, considers and approves such research. It was not feasible to contact each study 
participant of our cohort because of (i) pseudonymization, (ii) the retrospective design with 
occuring deaths prior to analyses, and (iii) the large sample size. 
Article 13 of the Helsinki declaration states that “Groups that are underrepresented in medical 
research should be provided appropriate access to participation in research.” Registries with 
nationwide coverage provide an opportunity for insights on misrepresented groups. Although 
exclusion criteria also applies for registration in SWEDEHEART, data representability for 
real-world patients is better than in many other types of research. For example, participation 
bias of clincial trials was possible to elucidate in Study IV. 
With the privilege of access to Swedish registry data for research, ethical obligations on 
another level follows. Swedish registry-based research has a high international reputation 
because the unique prerequisites for high-quality research has been well managed. 
SWEDEHEART-based studies are frequently published in high-impact medical journals. 
Other countries without comparable population and health registries, but with similarities 
regarding for example demography, wealth, and health infrastructure, are likely to assimilate 
Swedish registry-based research findings and apply them on their respective populations. 
Therefore, the high quality of the registry data must be matched by the research conduct 
including hypotheses of importance and high-quality methods for reliable results. 
In contemporary research, significant positive results are more likely to be published. 
Unfortunately, this publishing practice may lead to ethically unjustifiable selective reporting, 
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adaptations of research questions, methods, or in worst case, the underlying data. 
Counteractively, many medical journals have made it a condition of consideration for 
publication that the analysis plan of a clinical trial must be made publicly available in 
advance of trial conduct. No such demands apply to observational studies. Voluntary 
prospective public registration of analysis plans for non-trial studies are even sometimes 
discouraged by medical journals. Therefore, the ethical and moral responsibility not to 
deviate from a predefined hypothesis towards data-driven results is high within registry-based 
research. 
In conclusion of this research ethics reflection, the potential benefits of conducting the studies 
of this thesis by far exceeded potential risks for individual study participants. Furthermore, 
registry-based research is associated with an ethical obligation towards study participants to 






Main results are summarized in this section. For detailed reports of results, the reader is 
referred to the full manuscripts appended at the end of this thesis. 
5.1 STUDY I 
29,226 study participants were studied. Mean (SD) age was 63.1 (8.1) years and 26.9% were 
women. Higher income was associated with higher educational level and being married. 
Lower SES was associated with female sex, smoking, depressed LVEF, treatment for 
diabetes, body mass index, and lower eGFR. Higher SES groups were more likely to use 
statin therapy and participate in patient educational sessions and diet courses, and less likely 
to use diuretics. 
During the mean 4.1-year follow-up, there were 2284 (7.8%) rASCVD. All three SES 
indicators were associated with rASCVD and the strongest association was observed for 
disposable income (Figure 2). In multivariable Cox regression analysis with mutually 
adjusted indicators of SES (Figure 3), adjustments for clinically relevant CV risk factors in 
model II attenuated risk estimates, whereas further adjustment for identified differences in 
secondary prevention therapy did not. 
 
Figure 2. Kaplan Meier estimate depicting the rASCVD-free proportion by disposable income quintile. 
Abbreviations: rASCVD, first recurrent atherosclerotic cardiovascular disease event. Q, quintile. 
Ohm J, Skoglund PH, Discacciati A, et al. Socioeconomic status predicts second cardiovascular event in 29,226 survivors of a 
















Figure 3. Estimates of the associations 
between SES-indicators and rASCVD by 
analysis model depicted with Forest 
plots.  
Model I was adjusted for age, sex, and 
calendar year. Model II was adjusted for 
multiple CV risk factors. Model III added 
treatment with statins and diuretics, 
particiaption in patient educational 
session and dietary advice course.  
Ohm J, Skoglund PH, Discacciati A, et 
al. Socioeconomic status predicts 
second cardiovascular event in 29,226 
survivors of a first myocardial infarction. 
Eur J Prev Cardiol. 2008;25(9):985-993, 
by permission of Oxford University 
Press. 
 
In subgroup analysis by sex, the proportion of rASCVD was higher among women (8.2% vs. 
7.7% among men). No association between SES and rASCVD was detected in the female 
subgroup. Sex interactions was observed in the association between disposable income and 
rASCVD which indicated greater effect on risk among men (p<0.05). Sex interaction was 
also observed in the association between marital status and rASCVD which indicated that 




5.2 STUDY II 
In the final study cohort (n=25,643), median (IQR) age was 63.3 (56.4, 68.8) years, 27% 
were women, and 96.9% were on statin therapy at the 2-month revisit according to data on 
claimed drug prescriptions from the National Prescribed Drugs Register. Study participants 
with lower LDL-C levels were typically older, men, non-smoking, obese, and were treated 
for hypertension and diabetes. Lower levels of LDL-C was associated with claiming 
prescriptions for more intense statin therapy and use of RAAS inhibitors. Levels of total 
cholesterol and triglycerides but not HDL-C were clearly correlated with level of LDL-C. 
During a mean 4.1-year follow-up, rASCVD occurred in 8.5% of study participants 
(n=2173). Achieved levels of LDL-C and total cholesterol were associated with a moderate 
risk of rASCVD, but only in the highest vs. referent lowest quintile and weaker for LDL-C 
than for total cholesterol. (Figure 4) Achieved levels of HDL-C in the third to fifth quintiles 
vs. the lowest were associated with lower risk of rASCVD and the greatest risk reduction was 
observed in the median quintile. For achieved levels of triglycerides, increasingly strong 
associations with rASCVD was observed from the third to the fifth quintiles vs. the lowest. 
 
 
Figure 4. Association between continuous lipid fraction levels modelled with restricted cubic splines and rASCVD. The median 
lipid level in the lowest quintile of each lipid fraction was set as the referent value. 
Abbreviations: LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; rASCVD, first recurrent 
atherosclerotic cardiovascular disease event. 





The discriminatory capacity of the TIMI Risk Score for secondary prevention108, derived 
from a trial cohort, was poor (C-index <0.6) when applied to the study sample. Addition of 
each lipid fraction, including LDL-C, to the prediction model improved measures of 
predictive accuracy significantly, but changes were negligibly small. 
In a complementary Cox regression analysis, the acknowledged secondary prevention 
treatment target for lipid levels, LDL <1.8 mmol/L, was used as the referent category. Only 
621 study participants with LDL-C ≥4.0 mmol/L were associated with higher risk of 
rASCVD. (Figure5) 
 
Figure 5. Forest plot depicting hazard ratios and 95% CIs using the recommended treatment target, LDL-C <1.8 mmol/L as the 
referent category. Model I was crude. Model II was adjusted for age, sex, and calendar year. 
 
Analysis in the subgroup treated with high-intensity statins (n=6907), neither LDL-C or total 
cholsterol were associatiated with rASCVD while attenuated associations remained for 
triglycerides and HDL-C. Additional adjustment for changes in statin therapy intensity after 
basline did not appear to affect main results, except that no associations with rASCVD was 
observed between the lowest and higher levels of LDL-C. In secondary outcome analyses, 
associations were overall similar, except that no associations were observed between levels of 
LDL-C and fatal or nonfatal stroke and that higher quintiles of LDL-C were associatied with 




5.3 STUDY III 
A final sample of 30,191 study participants was identified. Mean age (SD) was 63.0 (8.6) 
years and 27.1% were women. Co-indicators of SES were strongly associated with one other. 
Mean age and frequencies of previous hypertension, dyslipidemia, and congestive heart 
failure, eGFR, and STEMI were similar across income quintiles. Lower income quintiles 
were associated with smoking, obesity, diabetes, the metabolic syndrome, non-sinus 
admission ECG, atypical presenting symptoms, and more extensive coronary disease with 
higher peak troponin levels, obstruction of more coronary vessels, and more depressed 
LVEF. Higher income quintiles were associated with more frequent angiography, PCI in 
cases of angiographic indication, and primary PCI in cases of STEMI. 
The proportion achieving risk factor targets was typically low and worse in lower income 
groups. Higher ORs in the highest vs. lowest income quintile were observed for achieving 
smoking cessation, target levels of blood pressure and glycated hemoglobin (HbA1c) (Figure 
6). Associations between indicators of SES and achieved LDL-C target and weekly physical 
activity were inconsistent. 
 
Figure 6. Tabulation and Forest plot of the associations between disposable income and secondary prevnetion treatment 
targets.  
a ≥ moderate exertion ≥ 5 times lasting 30 minutes. 
b LDL-C target according to changed recommendation in 2012 from LDL-C <2.5 to <1.8 mmol/L.  
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Frequencies of secondary prevention utilization were typically high for evidence-based drug 
therapies, low for participation in cardiac rehabilitation programs and patient monitoring 
activities, and better in higher income quintiles. Associations with participation in 
comprehensive cardiac rehabilitation was observed for all indicators of SES. The highest vs. 
lowest income quintile was strongly associated with participation in physical training 
programs, patient educational sessions, and stress management group sessions, and 
moderately associated with participation in dietary advice courses. (Figure 7) The highest vs. 
lowest income quintile was associated with more frequent lipid profile measurements, 
intensification of statin therapy after revisits, use of statins, and use of high-intensity statins at 
the 1-year revisit. Associations were observed between higher SES and discharge with dual 
antiplatelet therapy, statins and RAAS inhibitors. At the 1-year revisit, higher SES was 
associated with using statins, high-intensity statin therapy and RAAS inhibitors.  
 
Figure 7. Forest plot depicting estimates of the association between disposable income and secondary prevention activities 
throughout the first year after myocardial infarction. 
Associations between disposable income risk factor targets and secondary prevention 
utilization were similar among men and women. However, the odds of achieving blood 
pressure target was stronger among women than men in the highest income quintile and the 
odds of statin use at the 1-year revisit was stronger among men than women in the highest vs. 
lowest income quintile.  
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5.4 STUDY IV 
The final study cohort comprised 31,792 individuals. There were 2,941 trial participants and 
28,851 individuals who had not participated in a clinical trial after the index MI. Between the 
groups, mean age was similar. Trial participation was associated with male sex, higher 
income, higher educational level, and being married. Non-participation in a trial was 
associated with a history of stroke and MI, smoking, symptoms of anxiety and depression, 
reduced LVEF, low eGFR, worse mean lipid levels, and non-sinus rhythm at the 1-year visit. 
Prevalence of diabetes and mean values of blood pressure and body mass index were similar 
between groups (Figure 8). Trial participation was associated with use of acetylsalicylic acid 
and RAAS inhibitors, participation in physical training and patient educational programs 
within cardiac rehabilitation whereas non-participantion was associated with use of diuretics, 
nitrates and oral anticoagulants. 
 
Figure 8. Forest plot depicting the risk ratios with 95% CIs estimated with Poisson regression between participants and non-
participants in clinical trials after myocardial infarction. 
Abbreviations: MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; LVEF, 
left ventricular ejection fraction; eGFR, estimated glomerular filtration rate; BMI, body mass index; HDL-C, high density 














Figure 9. Kaplan Meier 
estimate of ASCVD event-
free proportion between 
participants and non-
participants in clinical trials 
after myocardial infarction 






During a mean 6.7-year follow-up, rASCVD occurred in 16.4% individuals in the study 
population. The 10-year absolute difference in rASCVD-free proportion between groups was 
4.2% (Figure 9). Trial participation was associated with lower crude risk of rASCVD that 
was independent of adjustments for age, gender, and calendar year. Further adjustment for 
clinical risk factors and comorbidities, but not secondary prevention use, attenuated the 
association between trial participation status and rASCVD. Final model adjustments for SES 
indicators attenuated the association further. However, a lower risk in trial participants 




5.5 STUDY V 
The study cohort was the same as in Study III. Summarized descriptive results and 
comparisons between disposable income levels and co-indicators of SES, CV risk factors, 
variables related to MI presentation and severity, initial therapies, and secondary prevention 
use are reported above.  
Figure 10. Association between disposable income quintiles and rASCVD estimated in five sequential models for hazard ratios 
with 95% CIs presented as forest plots.  
During a mean 7.4-year follow-up, rASCVD occurred in 14.2% of the 31,191 study 
participants. The lowest vs. highest income quintile was strongly associated with rASCVD in 
a bias-minimized model adjusted for age, gender, and calendar year (Figure 10). In sequential 
models, excessive risk in the lowest income quintile was attenuated by adding traditional risk 
factors, but not substantially by additional adjustment for acute presentation, infarct severity, 
and initial therapies. Further attenuation was observed in the final model that was additionally 
adjusted for secondary prevention activities. 
Participation in physical training programs and patient educational sessions within cardiac 
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vs. highest income quintile whereas optimal statin management did not. The proportion of 
excess rASCVD risk in the lowest income quintile through a potential mediator by follow-up 
year is presented in Figure 11. Estimated mediating proportions were small. 
 
Figure 11. Proportion of the total excess probability of rASCVD due to income in the lowest quintile mediated through a 
plausible mediator. In Panels A-D, the plausible mediator was participation in physical training program, participation in patient 
educational sessions, optimal statin therapy, and the metabolic syndrome, respectively. The mediating proportions were the 
excess probability of rASCVD associated with an income in the lowest quintile attributed to its estimated mediating natural 
indirect effect for a potential mediator. The total risk was the complement of the survival function and was based on a model 
adjusted for age, sex, and calentar year. The plausible mediator was assessd in logistic regression. 
In sensitivity analyses with mutually adjusted indicators of SES, associations between 
disposable income and rASCVD were attenuated but remained strong. The associations 
between marital status and rASCVD was moderately strong and independent of all adjusting 
factors. Educational level was the weakest SES indicator for rASCVD. Complete case 
analysis estimates were similar to results in the full cohort. 
Secondary outcomes CV death and all-cause death during mean 7.9 years of follow-ups 
occurred in 4.5% and 12.4% study participants, respectively. The risk gradients by disposable 
income quintile were stronger for secondary outcomes than for rASCVD. In sequential model 
analysis, prior risk factor accumulation and secondary prevention activities, but also MI 




In this thesis, the importance of risk factors in secondary prevention after MI and the role of 
SES in this population was studied in order to improve knowledge. A less established risk 
factor for CV risk assessment after MI, SES, was strongly associated with rASCVD in Study 
I. Between disposable income, educational level, and marital status, associations were the 
strongest for disposable income. Study II demonstrated that the association between achieved 
on-treatment levels of LDL-C, an established measure for risk assessment, and rASCVD was 
weak and that lipid levels carried a minimal predictive value for long-term risk. Plausible 
mediation in the association between SES and rASCVD during the first year of secondary 
prevention was then assessed in Study III. Socioeconomic disparities were observed 
regarding use of therapies, monitoring, and risk factor target achievements that are 
recommended in clinical practice guidelines on CV prevention. Associations between SES 
and participation in cardiac rehabilitation programs intended for lifestyle modification were 
the strongest. There is room for improvements in secondary prevention after MI in general, 
and preferably through evidence-based recommendations. Study IV found that patients 
participating in clinical trials after MI were a highly selected group with higher SES, female 
under-representation, fewer CV risk factors, and better long-term prognosis. Hence, trial 
findings derived from the post-MI population may contribute with high-level evidence but at 
the expense of poor generalizability to low-SES groups, and the real-world post-MI 
population overall. In Study V, a mediating effect on excess risk for rASCVD in low SES 
was observed for cardiometabolic risk profile (the metabolic syndrome). Similar mediating 
effect sizes were observed for participation in cardiac rehabilitation programs (physical 
training programs and patient educational sessions), whereas optimal statin management did 
not mediate excess risk for rASCVD in low SES. 
6.1 RISK FACTORS WITH IMPORTANCE IN SECONDARY PREVENTION 
Conclusions from Study I and II were that SES, by proxy disposable income level, may be a 
better measure than on-treatment lipid levels in the assessment of risk for rASCVD within the 
post-MI population. 
6.1.1 Lipid Levels 
In Study II, on-treatment levels of LDL-C were weakly associated with rASCVD and the 
predictive value was negligable. The findings question whether the arbitrary LDL-C target 
level used in clinical practice38,124,125,159,160 can discriminate high-risk individuals from low-
risk individuals at revisits two months after MI for decisions on continued treatment intensity. 
The 2013 ACC/AHA guideline on the treatment of blood cholesterol abandoned LDL-C 
targets in lack of evidence.147 A study based on post-MI trial samples suggested that 
percentage LDL-C reduction was more predictive than achieved LDL-C levels for 
rASCVD.161 Study V align with findings from a meta-analysis comparing intensive vs. less 
intensive lipid lowering therapy in which there was evidence of increased mortality risk 
among patients with baseline LDL-C >2.6 mmol/L only162 and the ODYSSEY-OUTCOMES 
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trial in which results were driven by outcomes in the prespecified subgroup with LDL-C >2.6 
mmol/L.163 Study V findings do not question that LDL-C is a key causal component of 
atherosclerosis164, that there is overwhelming evidence in support of lipid lowering therapy 
with statins for reduction of ASCVD risk112,126, or that LDL-C is excellent for measuring 
baseline-risk in the general population. However, causal properties of a risk factor are 
irrelevant for risk prediction.165 However, in a secondary prevention population where 
virtually all post-MI patients are treated with potent statins, LDL-C is not a surrogate measure 
for adverse outcomes.166 
Shortly after the landmark trials on PCSK-9 inhibitors were published114,167, the 2019 ESC 
guideline on dyslipidemia recommended continued use of LDL-C target levels and that it 
should be lowered from <1.8 mmol/L to <1.4 mmol/L.125 A simulation study estimated that 
half of the Swedish post-MI population, even if all were treated with high-intensity statin 
therapy plus ezetimibe, would be eligible for PCSK-9 inhibition according to the guideline 
recommendations. Adding a PCSK-9 inhibitor would increase cost of lipid lowering 
treatment by thousands of percent, an increase from around €30 to €4500 a year for each 
eligible post-MI patient.168 The cumulative cost would be a considerable financial burden for 
the Swedish tax-financed health care system. Whether low-income groups would be 
disadvantaged remains for future research. In Study III, the highest (vs. lowest) income level 
was not associated with LDL-C target achievement at the the 1-year revisit.  
6.1.2 Socioeconomic Status 
SES is generally not considered to be a modifiable risk factor. As a risk factor on the 
individual-level, SES cannot be improved by health care professionals by any means. 
According to the WHO conceptual framework15,41, political economy, social policies and 
politics are a wider set of forces – a system – that shape “the circumstances in which people 
are born, grow up, live, work and age, and the system put in place to deal with illness.” These 
life circumstances rule the SES of an individual and encompass economic stability, social and 
community support, access and quality of education and health care, housing and 
neighborhood conditions. Individual life circumstances and SES in turn determine lifestyle 
and behavioral factors that determine levels of blood pressure, blood lipids, abdominal 
adiposity, and blood sugar - the most proximal causes of ASCVD. Our limited resources and 
efforts should not be too heavily focused on treating the “consequences of the consequences”. 
Instead, SES should be considered a fundamental, causal and modifiable risk factor.16,40  
An individual or family may change SES actively. For example by moving away from 
adverse elements of life circumstances, by pursuing education to migrate on the 
socioeconomic gradient over a life course, and SES may change through professional careers 
and marriages. For improvements of socioeconomic health equity, elimination of SES from 
society is not feasible. However, disparities of the life circumstances can be diminished 
through health policies and strategies, legislation, and resource allocation at national, regional 
and local levels of society and health care.169 For example, political actions such as 
prevention of active and passive smoking170, adverse dietary habits171 and promotion of youth 
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sports activities172 may reduce socioeconomic health disparities for future generations. In 
Sweden, the Public Health Agency (Folkhälsomyndigheten, FOHM) is responsible for this 
important work, alongside other major tasks.173 At the level of the healthcare system and 
clinical practice, focus may need to be stronger on lifestyle interventions. Further knowledge 
gains on secondary prevention risk mediation are warranted for efficient allocation of 
resource. 
In these studies, disposable income was the strongest indicator of SES when mutually 
adjusted for educational level and marital status. Disposable income was associated with 
utilization of secondary prevention, treatment targets, rASCVD and secondary outcomes. The 
data does not explain why these associations were observed. Healthcare services and 
prescription drugs are expensive but virtually fully covered by the Swedish tax-financed 
healthcare system. Nontheless, a low-income individual may be less willing to spend any 
amount of money on prescription drugs and health promoting activites such as fees for access 
to organized physical training. Low income may also affect the option of buying healthier 
food.171,174 Disposable income level, if long-standing, has also been suggested to be the best 
SES-indicator of material resources and living standards.175 With higher material standards, 
car ownership is more likely which in turn may improve access to cardiac rehabilitation and 
other health promoting facilities.176 Beneficial psychological effects from self-sufficiency is 
another plausible aspect. A limitation of using disposable income as indicator of SES is that 
income level may changes due to an event such as MI. Therefore, income levels collected in 
the year prior to baseline was used in all studies.  
Study I, III, IV, and V suggest that disposable income level carries information that is 
clinically relevant. Although frequently used as proxy for SES in research, income and other 
indicators of SES are often considered sensitive information. Patients and care providers may 
feel uncomfortable by the thought of discussing something that may be considered an 
intrusion of privacy.13,45,177 However, these hesitations are based on assumptions of the 
feelings of others and may be degradable boundaries set by social structures and culture. The 
same type of social forces that determine SES. Individual-level income was measured in this 
thesis, but income was categorized into fifths for study of group-level SES. As a reflection 
SES and life circumstances. The clinical relevance of our findings encourages clinical use of 
disposable income level as a measure to identify high-risk individuals post-MI eligible for 
specific or intensified therapy.   
6.2 SECONDARY PREVENTION IN STABLE PHASE AFTER MYOCARDIAL 
INFARCTION 
Study I findings generated hypotheses for Study III and V and a final conclusion that 
increased rates of participation in cardiac rehabilitation among low-SES groups may reduce 
long-term risk of recurrent ASCVD events and improve health equity. 
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6.2.1 Secondary Prevention Therapies 
It is well established that lowering of CV risk factor levels is associated with a reduction of 
ASCVD events.6,38 Use of lipid lowering therapies and anti-hypertensive drugs are evidence-
based in primary as well as secondary prevention83,84,112, although efficacy of beta blockers 
need reevaluation in the revascularization era population.86 In long-term secondary 
prevention, also platelet inhibitors are evidence-based.76 These therapies are cornerstones of 
secondary prevention management. Frequencies of usage among study participants in the 
thesis cohort were high overall. However, as reported in Study III, reported use of statins and 
RAAS inhibitors was lower among low-SES individuals 1 year after MI. Interventions for 
better drug therapy adherence in low SES may improve health equity.131,132,178 For example, 
the use of polypills has been suggested in order to simplify drug administration.7 
Interventions for lifestyle change may be crucial for achieving further overall reductions of 
recurrent ASCVD in Sweden. Just as secondary prevention drug therapies, cardiac 
rehabilitation is associated with improved outcomes and is evidence-based.92,93,179,180 
Although rates of participation in cardiac rehabilitation in Sweden are higher overall than in 
many other countries, few post-MI patients complete three months of physical training 
program.181 Therefore, a great potential for improvements remains to be achieved from 
lifestyle interventions through increased uptake of cardiac rehabilitation.94 In low SES, strong 
face-to-face endorsement for participation by the hospital physician appears to be effective 
but does not necessarily increase rates of completion.182,183 Cost of transportation and parking 
may affect attendance and home-based interventions may be effective and cost less.13,183 
Additionally, cardiac rehabilitation need better standardization, quality control, and work 
routines at centers throughout the country. Identification of cardiac rehabilitation components 
that matter most for prognosis has been warranted184 and Study V may contribute with some 
guidance. However, the mediating effects observed for participation in physical training 
program and patient educational sessions were small and interventions may not improve 
socioeconomic health equity substantially. In Study V, a small mediating effect was also 
observed for a cardiometabolic risk profile. Similar findings were reported in a recent 
primary prevention study on a lifestyle factor-index as a mediator between SES and CV 
outcomes.185 Hence, strengthening of primary prevention may reduce both incident and 
recurrent ASCVD in low SES. 
Study III reported that participation in cardiac rehabilitation programs was strongly 
associated with SES. Only 34% in the lowest income quintile participated in exercice based 
cardiac rehabilitation compared to 54% in the highest income group. In Study III, the 
association between SES and participation in stress mangement group sessions was also 
strong and self-reported symptom of depression and anxiety were more frequent among low-
SES individuals. These symptoms are associated with non-compliance after MI90,186 as well 
as with worse outcomes.187 Overlapping between SES and psychosocial factors may be 




6.2.2 Room for improvement 
As reported in the literature review of this thesis, the 2016 EUROASPIRE IV survey on CV 
risk factor target achievements and guideline adherence in secondary prevention after 
coronary events or interventions was discouraging.11 The 2019 EUROASPIRE V survey, on 
8,261 secondary prevention respondents from 27 European countries was not indicating any 
improvement.188 Risk factor levels and management adherence to guidelines varied between 
countries and were likely overestimated in general because of the major limitation of 
EUROASPIRE, participation-bias due to low rates (≈ 50%) interviewed. The secondary 
prevention sub-registry of SWEDEHEART represents the population of origin better than the 
multinational European sample of EUROASPIRE-respondents. According to 
SWEDEHEART, approximately 80% of all individuals hospitalized for MI who are under 75 
years attend the 1-year follow-up in Sweden. In comparison between attendants and the 
proportion lost to follow-up, non-attendants are higher-risk individuals who more frequently 
have a history of previous CV events than registered participants.10,181 Representability of 
SWEDEHEARTs secondary prevention registry has improved further in recent years. Since 
2018, 100% of cardiac care hospitals throughout Sweden are reporting and the upper age-
limit has been raised to 80 years of age. SWEDEHEART evaluates secondary prevention 
quality in detail. Four secondary prevention targets, besides registry completeness, are 
considered to be particularily important in assessment of quality of care and are assessed at 
the 1-year revisit: targets for blood pressure level and LDL-C, participation in physical 
training program within cardiac rehabilitation, and smoking cessation. Smoking cessation has 
been achieved in approximately 55% of smokers in annual follow-ups during the past decade 
whereas the proportion achieving blood pressure targets and LDL-C targets continuously 
improve.181 In 2014, only 16% of Swedish 1-year survivors of MI achieved all four targets.10 
Between 2014 and 2019, the proportion participating in a physical training program after MI 
increased marginally but has stagnated at approximately 20%.181 Epidemiological studies are 
fundamental for better understanding of secondary prevention circumstances and the 
SWEDEHEART secondary prevention sub-registry serves as a unique platform. An 
extension of the continuous efforts of developing SWEDEHEART is higher potential of 
deriving epidemiological studies that may further improve secondary prevention care. 
6.3 METHODOLOGICAL CONSIDERATIONS 
Logistic regression was used in Study III and as part of mediation analysis of Study V. 
Logistic regression describes the association between an exposure and a dichotomous 
outcome as odds ratios.189 
Poisson regression was used for in Study IV for estimates presented as risk ratios that are 
more intuitively interpreted than odds ratios. Poisson regression is a linear model on the log-
scale. That is, the method applies a logarithm transform and is used for outcomes that are 
counts distributed by the Poisson distribution. Proportional risk rate and constant risk rate 
over time is assumed.190  
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Kaplan-Meier estimates were used to visualize associations between exposures and 
outcomes over follow-up time. Kaplan-Meier is a descriptive method to display time-to-event 
analysis. An assumption of the method is that censoring is independent of time. That is, 
migration or competing risks are not accounted for.190  
Cox proportional-hazards regression analyses were used in used Studies I, II, IV, and V. 
Cox regression is a flexible and popular method for time-to-event analysis that is based on 
Poisson regression but does not require constant hazard rate during observation time. 
Compared to Kaplan-Meier estimates, Cox regression handles censoring. There is no 
assumption of constant hazard rate, however that hazard rate between compared groups is 
proportional throughout the observation time. This was verified by means of scales of 
Schoenfeld’s residuals.190  
Harrell’s C-index (or C-statistic or the area under the curve plotted from sensitivity by the 
complement of specificity) is frequently used to estimate predictive performance or accuracy. 
C-index evaluate the discriminatory capacity of a test. That is, how well a test separates cases 
from non-cases.152 A weakness is that significant differences in absolute risk may render 
small changes of C-index, in particular when the base model used for evaluation of a 
candidate predictor includes powerful predictors.154 
continuous Net Reclassification Index (cNRI) and Integrated Discrimination 
Improvement (IDI) are tests of reclassification that complement discrimination testing. 
Reclassification tests evaluate how well a model classifies individuals to different (clinically 
relevant) risk-strata. For example, NRI calculates whether cases are more likely to be 
recategorized to a higher risk strata and non-cases are more likely to be recategorized to 
lower risk strata when a candidate predictor is added to the model. Reclassification tests used 
in Study II were non-categorical (that is, cNRI calculates the proportion of cases in whom 
risk is increased, and the proportion of non-cases in whom the risk level is decreased, 
compared with the reference prediction model. IDI indicates the proportion explained 
variation154,155. The reclassifications have been criticized for overestimating model 
performance.191 
Causal mediation analysis was performed in Study V using an advanced method for 
mathematically consistent causal interpretation of causal mediation on observational data. 
The method combines multivariable time-to-event analysis with logistic regression data for 
estimates on causal natural indirect (i.e. mediating) and direct effects through a candidate 
mediator in the association estimated with time-to-event data.156,157 Mediation analysis is a 
growing field in epidemiology and biostatistics. Several types of bias may arise including 
backdoor path bias, non-collapsability of hazard ratio, and intermediate confounding. The 
method used in Study V was based on the counterfactual framework which is considered to 




6.4.1.1 Study design 
All studies in this thesis were registry-based observational retrospective cohort studies. Major 
limitations of the observational study designs include risk of residual confounding and 
incompatability with making causal inferences. Retrospective use of registry-data limited 
control of variable choice. In Study II, data on lipid levels at admission for the index MI were 
not available. At the time of data extraction, no variable existed that accounted for dietary 
habits.  
Neither patient-reported use, records of physician prescriptions, or pharmacy claims of 
prescriptions reveal whether drug therapies actually enter the blood stream of a patient. In 
studies on SES after MI, where adherence to drug is likely important, such data would have 
been desirable. SWEDEHEART collects data on drug therapies reported before MI, at 
discharge from initial care, and at the 2-month and 1-year revisits after MI. In Study II, III, 
and V, further detailed data on drug therapy intensity was added through linkage from the 
National Prescribed Drug Register. However, there was no way to account for patient 
adherence to medication.  
6.4.1.2 Erroneous data 
Even though SWEDEHEART data were entered directly on site by health care professionals, 
entry was manually and occasional human error is inevitable. This may introduce random 
erroneous data that is more or less obvious (for example, body mass index 92 instead of 29 
vs. body mass index 32 instead of 23). Bias may be introduced from variable definitions that 
differ from clinical interpretation (for example, definitions for ECG annotation data entry). 
Smoking cessation program and dietary advice course were not options at all cardiac 
rehabilitation sites throughout the country and were available as variables for registration for 
a limited period only. Hence, participation status may be unrelated to SES and findings 
regarding these variables in Study III and V should be interpreted with caution. Variables 
may also be not missing at random which introduces bias that is difficult to account for in 
retrospect. Furthermore, in the process of merging datasets, selecting variables, and other 
parts of data management, errors may have been introduced. Throughout the thesis, work was 
performed in close cooperation with statisticians tied to the project in order to minimize 
errors in data management and analyses. 
6.4.1.3 Exposures 
Data from Statistics Sweden was near complete on indicators of SES. However, disposable 
income may be biased for many reasons. For example, individuals of a household where one 
spouse earn enough to provide for the other would be misclassified. We handled this bias by 
choosing a type of disposable income that account for household income, size, and 
composition. Inevitably, misclassification would persist in plausible high-income households 
with the incitement of reporting low annual incomes to evade taxation.  
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Despite having chosen three indicators of SES for Study I, comparison to the findings of 
other studies on SES is a difficulty in research on SES. For example, a recent meta-analysis 
of 1.7 million study participants investigated the associations between SES and CV risk 
factors, and mortality. However, a European classification of occupational status was used as 
proxy for SES.169 Indicator selection and the number of indicators used to measure SES affect 
usability of findings. Occupational status was available but actively not chosen when this 
doctoral project was initiated because of difficulties categorizing occupations that undergo 
changes in societal status over time.  
A potential limitation of restricting the choice of SES indicators to the individual-level is that 
neighborhood or regional socioeconomic circumstances may carry information relevant to 
underlying mechanisms to the association between SES and rASCVD. For example, driving 
distance to health care facilities is associated with attendance to cardiac rehabilitation176 as 
pointed out in Study III. This information has potential importance for decisions on resource 
allocations. 
The trial participation variable used in Study IV was near complete with missing values 
reported for less than two percentages of eligible study participants attending the 1-year visit 
after MI. A limitation was that no information was available on reasons for non-participation 
in a clinical trial. For example, whether a study participant had been made the offer to 
participate in a clinical trial.  
6.4.1.4 External validity 
Representability is discussed as a strength of all studies in this thesis, with good reason, and 
was hypothesis generating for Study IV. Therefore, a reflection in this thesis discussion is that 
extrapolation of SWEDEHEART-based findings also warrant caution. SWEDEHEART 
completeness is high. However, 20% of eligible post-MI patient are lost to follow-up. This 
population have a worse CV risk profile and there is good reason to believe that they have 
lower SES considering the established associations between SES and adherence and CV risk 
profile. Furthermore, registry coverage or completeness refers to the number of patients that 
are eligible for inclusion. The upper age limits for SWEDEHEART inclusion and the fact that 
only individuals hospitalized for MI were eligible must be considered in interpretation of 
study findings of this thesis. A considerable proportion of all MIs occurring in the country are 
unaccounted for. Our findings may not apply to individuals with an advanced age, who have 





7.1 STUDY I 
SES was strongly associated with rASCVD among patients in stable phase after first-ever MI 
in a large Swedish cohort with nationwide representation. The strongest indicator of SES was 
disposable income, and the association with rASCVD was independent of most traditionally 
considered CV risk factors. Hence, SES should be considered in risk assessment post-MI for 
clinical decisions on secondary prevention intensity.  
7.2 STUDY II 
LDL-C achieved 2 months after a first-ever MI was the routinely measured lipid fraction with 
the weakest association with rASCVD. The strongest association was observed for level of 
triglycerides. Furthermore, lipid levels carried minimal incremental predictive value on top of 
other traditional CV risk factors in a secondary prevention prediction model. Consequently, 
our data questions the use of LDL-C levels achieved at the 2-month revisit for risk 
assessment and decisions on continued treatment intensity. 
7.3 STUDY III 
Among 1-year survivors after MI in the tax-financed health care system of Sweden, lower 
SES was associated with worse utilization of target-oriented secondary prevention activities 
including patient monitoring, participation in cardiac rehabilitation programs for lifestyle 
change, and use of evidence-based drug therapies. Lower SES was also associated with worse 
achievements of 1-year risk factor targets. The observed socioeconomic disparities were 
indicating a causal chain and a plausible explanatory mechanisms for higher long-term risk of 
rASCVD in lower SES.  
7.4 STUDY IV 
Among patients surviving 1 year after MI, those who took part in a clinical trial were more 
often male, had higher SES, a healthier risk factor profile, were more likely to recieve 
recommended secondary prevention therapies, and had better prognosis than those who did 
not take part in a clinical trial. Additional unmeasured participation bias was implied. 
External validity of post-MI trials is questionable. In particular risk factor profile and SES 
should be carefully considered in application of clinical trial findings on real-world patients.  
7.5 STUDY V 
Socioeconomic disparities regarding CV risk profile and utilization of secondary prevention 
were explanatory factors for worse prognosis in low SES after first-ever MI. Participation in 
core cardiac rehabilitation programs during the year after MI were identified as risk 
mediators. Therefore, improved cardiac rehabilitation uptake in lower SES may improve 
health equity. Findings were also indicating that improved primary prevention management 
of the metabolic syndrome in low SES may reduce the risk for recurrent ASCVD. 
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7.6 OVERALL CONCLUSIONS 
The overall aim of this thesis was to improve the knowledge about risk factors with 
importance in secondary prevention among patients in stable phase after MI, with special 
focus on prognosis and SES. Risk assessments based on SES, measured by disposable 
income level, may be preferable over achieved levels of LDL-C for the identification of high-
risk individuals after MI. Low SES was associated with worse achievements of guideline-
directed treatment targets and use of target-oriented secondary prevention activities. SES 
disparities regarding participation in physical training program and patient educational 
sessions within cardiac rehabilitation programs and the metabolic syndrome risk profile were 
identified as mediators in the association between SES and rASCVD. Although the observed 
mediating effects were small, these findings provide modifiable targets for action to improve 
health equity after MI. Specific interventions must be evaluated in clinical trials. These trials 
should take into consideration that SES was a contributor to the participation bias of clinical 




8 POINTS OF PERSPECTIVE 
Observation of a strong associaton between SES and rASCVD, and a weak association 
between achieved LDL-C levels and rASCVD, may be useful to better identify high-risk 
individual at revisits after MI in Sweden. Regardless, risk prediction post-MI remains an area 
of secondary prevention research in need for improved methods.7 Existing secondary 
prevention risk scores are often derived from highly selected trial samples or heterogenoeous 
populations.108,193,194 Unless externally validated among post-MI patients with adequate 
predictive performance, useability is uncertain. A risk prediction score for the well-defined 
population that attend routine revisits after MI should be developed. At these revisits, the risk 
levels for rASCVD are elevated and have stabilized, several treatment options at different 
intensities exist to choose from, and the organization and resources are at hand for 
individualized risk-based interventions. SWEDEHEART and other national registries provide 
unique opportunities for the purpose of risk prediction modelling post-MI which should be 
pursued.134,137,141  
From a long-term perspective, stretching over generations, much can be, and is being done at 
the political level for improvements of public health and health equity after MI.173 Focus may 
need to be stronger on actions further up in the hierarchical chain of causality described by 
the WHO. At the clinical level, even stronger focus may be required on lifestyle than more 
easily measured secondary CV risk factors.38 Further study is needed to pinpoint causal 
pathways in the associations between SES and rASCVD. Although a mediating effect in the 
association between income and rASCVD was observed for cardiac rehabilitation programs 
and the metabolic syndome, the effects were small and need experimental confirmation. 
Regional differences in SES as well as cardiac rehabilitation content and accessibility may 
add information that is important for decisions on resource allocation. Other mediating 
pathways must be further explored, such as plausible differences in adherence to post-MI 
drug therapies.131,132,178 Interventions for cardiac rehabilitation uptake among low-SES 
individuals may improve secondary prevention achievements and health equity. An obstacle 
of designing and conducting trials post-MI regarding interventions on risk mediators in the 
association between SES and rASCVD may be the under-representation of women195,196 and 
lower-SES individuals. Further investments in conducting novel registry-based randomized 
clinical trials138 may improve generalizbility of trial findings to lower-SES groups. 
Further study is warranted on the predictive value of on-treatment LDL-C and whether LDL-
C target level should be used. For example, a randomized clinical trial comparing two LDL-C 
target levels. Unclarity of the evidence is demonstrated by the changing and conflicting 
recommendations from major professional organizations.38,124,125,147,159,160 Many LDL-C 
target recommendations are accompanied by an relative LDL-C level reduction.161 If Study II 
was to be redone, data on lipid levels at admission should be acquired to enable additional 
analysis assessing the associations between relative LDL-reduction reduction and recurrent 
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